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General Considerations: All reactions were carried out under a nitrogen atmosphere 
using oven or flame-dried glassware. All palladium complexes, ligands, and reagents 
were obtained from commercial sources and used without further purification unless 
otherwise noted. All amines were distilled from CaH2 prior to use in reactions. (S)-tert-
ButylPHOX,[1] 2-allylphenyl trifluoromethanesulfonate,[2] 2-allylnaphthalen-1-yl 
trifluoromethanesulfonate,[3]  2-allyl-4-fluorophenyl trifluoromethanesulfonate,[4] 2-allyl-4-
methoxyphenyl trifluoromethanesulfonate,[4] 1-allyl-2-oxo-cyclopentanecarboxylic acid 
S2 
 
ethyl ester,[5] 2-allylcyclopentan-1-one,[6] 2-allylcyclohexan-1-one,[6] 2-
cinnamylcyclopentan-1-one,[6] 3-allyltetrahydro-4H-pyran-4-one,[6,7] tert-butyl 3-allyl-4-
oxopiperidine-1-carboxylate,[6] allyl 2-oxocylopentane-1-carboxylate,[8] allyl 2-
oxocyclohexane-1-carboxylate,[8] allyl 1-methyl-2-oxocyclohexane-1-carboxylate,[9] 2-
allyl-2-methylcyclohexan-1-one,[10] N-(2-pyridyl)triflimide,[11] N'-3,4-dihydro-2H-
naphthalenylidene-N,N-dimethylhydrazine,[12] 2-allyl-2-methylcyclohexane-1,3-dione,[13] 
3,3-dimethylhex-5-en-2-one,[14] methyl 2-phenylpent-4-enoate,[15] 2-methyl-2-
phenylpent-4-enoic acid,[16] 3,3-diallylhex-5-en-2-one[17] were prepared according to 
published procedures. Alkenyl triflate compounds (9a-e, 11, 13a-d, 17a-b, 19a-c, 22a-
b) were stored in a freezer under nitrogen due to observed decomposition of 5-
allylcyclopent-1-en-1-yl trifluoromethanesulfonate (13a) when stored at ambient 
temperature for prolonged periods of time. Toluene, tetrahydrofuran, diethyl ether, 
diisopropylamine and dichloromethane were purified using a GlassContour solvent 
system. All yields refer to isolated compounds that are estimated to be ≥95% pure as 
judged by 1H NMR analysis, unless noted otherwise. The diastereomeric ratios were 
determined by 1H NMR analysis. The yields reported in the supporting information 
describe the result of a single experiment, whereas yields reported in Tables 1-5 and 
equations 1-4 are average yields of two or more experiments. Thus, the yields reported 
in the supporting information may differ from those shown in Tables 1-5 and equations 
1-4. 
Preparation and Characterization of Substrates 
 
(±)-6-Allylcyclohex-1-en-1-yl trifluoromethanesulfonate (9a). Following a procedure 
reported by McMurry,[18] a solution of 2-allylcyclohexan-1-one[6] (824 mg, 5.96 mmol) in 
THF (12 mL) was added dropwise over 30 min to a solution of LDA (6.56 mmol) in THF 
(18 mL) at –78 ºC and stirred for an additional 2 h. A solution of N-phenyl-
bis(trifluoromethanesulfonimide) (2.28 g, 6.38 mmol) in THF (12 mL) was then added 
dropwise over 30 minutes at –78 ºC. After addition, the mixture was warmed to 0 ºC and 
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stirred until the starting material had been completely consumed as judged by TLC 
analysis. The solvent was removed in vacuo and the resultant yellow oil was purified by 
column chromatography to affording the title compound (1.29 g, 80%) as a volatile clear 
oil. 1H NMR (500 MHz, CDCl3)  5.79 (td, J = 4.1, 1.4 Hz, 1H), 5.73 (dddd, J = 16.7, 
10.4, 7.8, 6.5 Hz, 1H), 5.16 – 5.00 (m, 2H), 2.51 (dt, J = 8.5, 4.8 Hz, 1H), 2.45 (dddt, J = 
13.3, 6.6, 3.2, 1.4 Hz, 1H), 2.19 - 2.10 (m, 3H), 1.87 - 1.81 (m, 1H), 1.72 – 1.46 (m, 3H); 
13C NMR (100 MHz, CDCl3)  151.90, 135.19, 119.53, 118.67 (q, J = 324.1 Hz) 117.65, 
37.28, 35.98, 27.76, 24.49, 19.08; IR (film) 1201, 1413 cm-1; MS (EI) 270.0543 
(270.0538 calcd for C10H13F3O3S, M+).  
 
 
(±)-3-Allyl-3,6-dihydro-2H-pyran-4-yl trifluoromethanesulfonate (9b). The title 
compound was prepared using a procedure analogous to that described above for the 
preparation of (E)-5-cinnamylcyclopent-1-en-1-yl trifluoromethanesulfonate except 3-
allyltetrahydro-4H-pyran-4-one[6,7] was employed as the starting material, and the 
reaction mixture was stirred -41 ºC for 3 h. This procedure afforded the title compound 
(1.1 g, 78%) as a clear oil. 1H NMR (500 MHz, CDCl3)  5.84 (t, J = 2.9 Hz, 1H), 5.75 
(dddd, J = 16.0, 10.1, 8.1, 5.9 Hz, 1H), 5.18 – 5.07 (m, 2H), 4.25 (q, J = 2.9 Hz, 2H), 
3.78 (t, J = 3.4 Hz, 2H), 2.54 – 2.41 (m, 2H), 2.28 (dt, J = 14.1, 9.4 Hz, 1H); 13C NMR 
(175 MHz, CDCl3)  148.56, 134.41, 118.61 (q, J = 318.4 Hz), 118.28, 117.22, 67.86, 
64.44, 37.99, 33.70; IR (film) 1206, 1140 cm-1; MS (EI) 272.0322 (272.0330 calcd for 
C9H11F3O4S, M+).  
 
 
(±)-N-Boc-3-allyl-4-{[(trifluoromethyl)sulfonyl]oxy}-3,6-dihydropyridine (9c). The 
title compound was prepared using a procedure analogous to that described above for 
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the preparation of (E)-5-cinnamylcyclopent-1-en-1-yl trifluoromethanesulfonate except 
tert-butyl 3-allyl-4-oxopiperidine-1-carboxylate[6,7] was employed as the substrate and 
the reaction mixture was stirred at –41 ºC for 3h. This procedure afforded the title 
compound (974 mg, 34%) was afforded as a clear oil. 1H NMR and 13C NMR spectra 
were sufficiently broadened and complex due to rotamers. 1H NMR (700 MHz, CDCl3)  
5.85 – 5.67 (m, 2H), 5.18 - 5.09 (m, 2H), 4.42 – 3.19 (m, 5H), 2.60 - 2.35 (m, 1H), 2.14 
(dt, J = 15.8, 8.9 Hz, 1H), 1.47 (s, 9H); 13C NMR (175 MHz, CDCl3)  154.63, 134.02, 
119.50, 118.38, 117.68, 80.69, 44.19, 41.73, 34.08, 28.49; IR (film) 1700, 1140 cm-1; 
MS (ESI) 394.0905 (394.0906 calcd for C14H20F3NO5S, M + Na
+). 
 
 
(±)-6-Allyl-6-methylcyclohex-1-en-1-yl trifluoromethanesulfonate (9d). The title 
compound was prepared according to a procedure reported by Cramer[19] except using 
2-allyl-2-methylcyclohexan-1-one[10] as substrate and diethyl ether as the solvent for the 
aqueous extraction. This procedure afforded the title compound (913 mg, 81%) as a 
clear oil. 1H NMR (400 MHz, CDCl3)  5.83 – 5.63 (m, 2H), 5.18 – 4.97 (m, 2H), 2.30 
(dd, J = 13.8, 6.9 Hz, 1H), 2.24 – 2.07 (m, 3H), 1.77 (ddd, J = 13.1, 9.6, 3.5 Hz, 1H), 
1.71 – 1.55 (m, 2H), 1.55 – 1.42 (m, 1H), 1.14 (s, 3H); 13C NMR (175 MHz, CDCl3)  
155.04, 133.54, 118.67, 118.52 (q, J  = 317.3 Hz), 117.22, 42.95, 38.27, 35.25, 24.91, 
24.46, 18.31; IR (film) 1200, 1413 cm-1; MS (EI) 284.0695 (284.0694 calcd for 
C11H15F3O3S, M+).  
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2-Allyl-2-methylcyclohexa-3,6-diene-1,3-diyl bis(trifluoromethanesulfonate) (9e). 
The title compound was prepared using a procedure analogous to that employed for the 
synthesis of 5,5-diallylcyclopent-1-en-1-yl trifluoromethanesulfonate except using 2-allyl-
2-methylcyclohexane-1,3-dione[10] as the substrate. This procedure afforded the title 
compound (1.2 g, 41%) as a white solid. 1H NMR (500 MHz, CDCl3)  5.86 (t, J = 3.8 
Hz, 2H), 5.65 (ddt, J = 17.1, 9.5, 7.4 Hz, 1H), 5.21 – 5.06 (m, 2H), 3.01 (q, J = 4.0 Hz, 
2H), 2.35 (d, J = 7.3 Hz, 2H), 1.41 (s, 3H); 13C NMR (175 MHz, CDCl3)  148.17, 
131.71, 119.71, 118.44 (q, J = 317.6 Hz), 113.39, 44.14, 39.63, 24.62, 22.84; IR (film) 
1211, 1140 cm-1; MS (EI) 429.9962 (429.9980 calcd for C12H12F6O6S2, M+).  
 
 
(±)-2-(But-3-en-2-yl)phenyl trifluoromethanesulfonate (11). The title compound was 
prepared according to a procedure previously reported by our group[4] except using 
crotyl bromide in place of allyl bromide. This procedure afforded the title compound (1.1 
g, 38% over 3 steps) as a clear oil. 1H NMR (700 MHz, CDCl3)  7.37 – 7.31 (m, 2H), 
7.31 – 7.21 (m, 2H), 5.96 (dddd, J = 16.3, 10.4, 5.9, 0.9 Hz, 1H), 5.15 – 5.04 (m, 2H), 
3.86 (qdd, J = 7.1, 5.8, 1.6 Hz, 1H), 1.37 (d, J = 7.0, 3H); 13C NMR (175 MHz, CDCl3)  
147.36, 140.98, 138.33, 129.35, 128.67, 128.03, 121.43, 118.74 (q, J = 318.2 Hz), 
114.68, 35.96, 20.09; IR (film) 1418, 1207, 1136 cm -1; MS (EI) 280.0388 (280.0381 
calcd for C11H11F3O3S, M+). 
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(±)-5-Allylcyclopent-1-en-1-yl trifluoromethanesulfonate (13a). The title compound 
was prepared using a procedure analogous to that employed for the synthesis of 6-
allylcyclohex-1-en-1-yl trifluoromethanesulfonate except using 2-allylcyclopentan-1-
one[6] as the substrate. This procedure afforded the title compound (959 mg, 48%) as a 
clear oil. The product was generated as an 8:1 mixture of regioisomers; data are for the 
major regioisomer shown. (Note: the enol triflate was stored under N2 at -8 
ºC to prevent 
decomposition). 1H NMR (700 MHz, CDCl3)  5.75 (ddt, J = 17.1, 10.2, 7.0 Hz, 1H), 
5.65 (app. q, J = 2.4 Hz, 1H), 5.15 – 5.03 (m, 2H), 2.99 – 2.84 (m, 1H), 2.44 – 2.29 (m, 
3H), 2.22 – 2.07 (m, 2H), 1.78 – 1.67 (m, 1H); 13C NMR (100 MHz, CDCl3)  151.53, 
134.91, 118.71 (q, J = 319 Hz), 117.44, 117.35, 42.77, 36.64, 26.79, 26.73; IR (film) 
1202, 1419 cm-1; MS (EI) 256.0389 (256.0381 calcd for C9H11F3O3S, M+).  
 
 
(±)-Ethyl 1-allyl-2-{[(trifluoromethyl)sulfonyl]oxy}cyclopent-2-ene-1-carboxylate 
(13b). Following a slight modification of a procedure reported by McMurry[20], a solution 
of 1-allyl-2-oxo-cyclopentanecarboxylic acid ethyl ester[5] (1.5 g, 7.64 mmol) in THF (15 
mL) was added dropwise over 30 min to a solution of LDA (9.17 mmol) in THF (31 mL) 
at –78 ºC. The solution was stirred at –78 °C for 2 h then a solution N-(2-
pyridyl)triflimide[11] (3.28 g, 9.17 mmol) in THF (18 mL) was then added dropwise over 
30 minutes at –78 ºC. After the addition was complete, the reaction mixture was warmed 
to rt and stirred overnight. The crude mixture was then diluted with water (20 mL) and 
extracted with diethyl ether (3 x 20 mL). The combined organic layers was dried over 
anhydrous MgSO4, filtered through a cotton plug, and concentrated in vacuo. The crude 
mixture was purified by column chromatography to afford the title compound (1.85 g, 
74%) as a clear oil. 1H NMR (400 MHz, CDCl3)  5.77 (t, J = 2.5 Hz, 1H), 5.69 (dddd, J 
S7 
 
= 17.0, 10.2, 7.7, 6.8 Hz, 1H), 5.21 – 5.09 (m, 2H), 4.27 – 4.09 (m, 2H), 2.64 (ddt, J = 
14.1, 7.8, 1.1 Hz, 1H), 2.53 – 2.41 (m, 3H), 2.41 – 2.27 (m, 1H), 2.08 – 1.96 (m, 1H), 
1.28 (t, J = 7.1 Hz, 3H); 13C NMR (175 MHz, CDCl3)  172.65, 148.09, 132.33, 119.62, 
118.55 (q, J = 316.7 Hz), 118.28, 61.74, 57.41, 38.95, 31.15, 26.32, 14.11; IR (film) 
1734, 1210 cm-1; MS (ESI) 329.0669 (329.0665 calcd for C12H15F3O5S, M + H
+) or 
346.0933 (346.0931 calcd for C12H15F3O5S, M + NH4
+).  
 
 
5,5-Diallylcyclopent-1-en-1-yl trifluoromethanesulfonate (13c). Following a 
procedure reported by Tsuji[21], a 25 mL Schlenk flask was flame-dried under vacuum 
and cooled under a stream of N2 (g). Pd2(dba)3 (104 mg, 2.5 mol %) and PPh3 (210 mg, 
20 mol %) were added and the tube was purged with N2 (g). A solution of 2-
oxocylopentane-1-carboxylate (673 mg, 4 mmol) in THF (12 mL) was added, followed 
by diallyl carbonate (1.15 mL, 8 mmol). The mixture was stirred at 65 ºC until the starting 
material had been completely consumed as judged by 1H NMR analysis (ca. 30 min). 
The solvent was removed in vacuo and the crude product was purified by column 
chromatography to afford 491 mg (75%) of 2,2-diallylcyclopentan-1-one as a clear oil. 
1H NMR (700 MHz, CDCl3)  5.77 – 5.62 (m, 2H), 5.12 – 5.01 (m, 4H), 2.26 – 2.07 (m, 
6H), 1.92 – 1.80 (m, 4H); 13C NMR (175 MHz, CDCl3)  222.45, 133.83, 118.54, 51.80, 
40.02, 38.62, 32.13, 18.87; IR (film) 3078, 1726 cm-1. 
Following a procedure reported by Cramer[19] that was slightly modified, solid 
KHMDS (716 mg, 3.59 mmol) was dissolved in THF (24 mL) in a flame-dried flask. The 
resulting solution was cooled to –78 ºC then 2,2-diallylcyclopentan-1-one (491 mg, 2.99 
mmol) in THF (6 mL) was added dropwise. The solution was allowed to stir for an 
additional 30 min at –78 ºC and then N-phenyl-bis(trifluoromethanesulfonimide) (1.18g, 
3.29 mmol) in THF (6.6 mL) was added and the mixture was stirred for 20 min at –78 ºC. 
The mixture was then warmed to rt, stirred for 1 h, then was quenched with satd. NH4Cl 
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(aq). The aqueous phase was extracted with EtOAc (30 mL x 3) and the combined 
organic layers were washed with brine, dried over anhydrous MgSO4, and concentrated 
in vacuo. The crude product was purified by column chromatography to afford the title 
compound (708 mg, 80%) as a clear oil. 1H NMR (500 MHz, CDCl3)  5.83 – 5.69 (m, 
2H), 5.63 (t, J = 2.7 Hz, 1H), 5.13 – 5.08 (m, 4H), 2.34 – 2.09 (m, 6H), 1.93 – 1.83 (m, 
2H); 13C NMR (100 MHz, CDCl3)  151.84, 133.56, 118.70, 118.60 (q, J = 318.7 Hz) 
114.43, 50.32, 41.96, 30.07, 26.19; IR (film) 1205, 1421 cm-1; MS (EI) 296.0693 
(296.0694 calcd for C12H15F3O3S, M+) 
 
 
(±)-(E)-5-Cinnamylcyclopent-1-en-1-yl trifluoromethanesulfonate (13d). Following a 
slight modification of a procedure reported by McMurry[18], to a stirring solution of LDA 
(4.94 mmol) in THF (20 mL) at –78 ºC was added a solution of 2-cinnamylcyclopentan-
1-one[6] (825 mg, 4.12 mmol) in THF (21 mL) over 30 min. The resulting solution was 
stirred at –78 °C for an 2 h, then a solution of N-(2-pyridyl)triflimide[11] (1.77 g, 4.94 
mmol) in THF (10 mL) was then added dropwise over 30 minutes at –78 ºC. After the 
addition was complete, the mixture was warmed to –41 ºC in CH3CN/dry ice bath and 
stirred for 2.5 h. The reaction was quenched at –41 ºC with satd. NH4Cl (aq) and the 
resulting biphasic mixture was warmed to rt. The aqueous phase was extracted with 
EtOAc (30 mL x 3) then the organic layers were combined, washed with brine, dried 
over MgSO4, and concentrated in vacuo. The crude product was purified by column 
chromatography to afford the title compound (1.18 g, 86%) as a clear oil. The product 
was afforded as a mixture of regioisomers (9:1); data are for the major regioisomer. 1H 
NMR (400 MHz, CDCl3)  7.38 – 7.27 (m, 4H), 7.23 (tt, J = 7.2, 1.7 Hz, 1H), 6.46 (dd, J 
= 15.8, 1.5 Hz, 1H), 6.15 (dt, J = 15.8, 7.2 Hz, 1H), 5.68 (app. q, J = 2.4 Hz, 1H), 3.10 – 
2.94 (m, 1H), 2.55 (dddd, J = 14.2, 7.3, 4.3, 1.4 Hz, 1H), 2.44 – 2.12 (m, 4H), 1.78 (qd, J 
= 7.4, 5.8 Hz, 1H); 13C NMR (100 MHz, CDCl3)  151.43, 137.44, 132.70, 128.68, 
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127.38, 126.48, 126.22, 118.7 (q, J = 319.0 Hz) 117.60, 43.17, 35.82, 26.84, 26.78; IR 
(film) 1418, 1204, 1138 cm -1; MS (EI) 332.0683 (332.0694 calcd for C15H15F3O3S, M+) 
.  
 
(±)-3,3-Dimethylhexa-1,5-dien-2-yl trifluoromethanesulfonate (17a). A flame-dried 
round bottom flask with a stir bar was cooled under a stream of N2 and charged with 
solid KHMDS (503 mg, 2.5 mmol) and THF (16 mL). The solution was cooled to –78 ºC 
with stirring, then a solution of 3,3-dimethylhex-5-en-2-one[14] (264 mg, 2.1 mmol) in 
THF (4 mL) was added dropwise. The mixture was stirred at –78 ºC for 1 h, then a 
solution of N-phenyl-bis(trifluoromethanesulfonimide) (900 mg, 2.5 mmol) in THF (5 mL) 
was added dropwise and stirring was continued at –78 ºC for 2 h. The cold solution was 
then poured over NaHCO3 (aq) (20 mL) into a separatory funnel. The aqueous layer 
was extracted using pentanes (3 x 25 mL). The combined organic layers were dried 
over anhydrous MgSO4, filtered, and concentrated slowly on rotary evaporator (T = 22 
ºC at -750 mbar). The crude material was purified by column chromatography to afford 
the title compound (333 mg, 61%) as a clear, volatile oil. 1H NMR (500 MHz, CDCl3)  
5.71 (ddt, J = 17.4, 10.1, 7.4 Hz, 1H), 5.15 – 5.03 (m, 3H), 4.92 (d, J = 4.4 Hz, 1H), 2.19 
(app d, J = 7.4 Hz, 2H), 1.15 (s, 6H); 13C NMR (175 MHz, CDCl3)  162.79, 133.37, 
118.65, 118.51 (q, J = 317.7 Hz), 101.23, 43.81, 39.69, 25.37; IR (film) 1418, 1213 cm-1; 
MS (EI) 217.0143 (217.0146 calcd for C6H8F3O3S, M
+ – ·CH2CH=CH2). Note: The 
molecular ion was not detected using EI or ESI techniques. The observed mass 
corresponds to loss of an allyl radical via fragmentation. 
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3,3-Diallylhexa-1,5-dien-2-yl trifluoromethanesulfonate (17b). The title compound 
was prepared using a procedure analogous to that employed for the synthesis of 5,5-
diallylcyclopent-1-en-1-yl trifluoromethanesulfonate, except using 3,3-diallylhex-5-en-2-
one[17] (1.1 g, 6.2 mmol) as the substrate. This procedure afforded 1.46 g (76%) of the 
title compound as a clear oil. 1H NMR (400 MHz, CDCl3)  5.72 (ddt, J = 17.4, 10.4, 7.3 
Hz, 3H), 5.28 (d, J = 4.7 Hz, 1H), 5.20 – 5.07 (m, 6H), 4.88 (d, J = 4.7 Hz, 1H), 2.21 (dt, 
J = 7.3, 1.2 Hz, 6H); 13C NMR (100 MHz, CDCl3)  159.40, 132.42, 119.26, 118.44 (q, J 
= 317 Hz), 103.26, 45.77, 38.07; IR (film) 1406, 1207, 1140, 915 cm -1; MS (EI) 
269.0463 (269.0459 calcd for C10H12F3O3S, M
+ – ·CH2CH=CH2). Note: The molecular 
ion was not detected using EI or ESI techniques. The observed mass corresponds to 
loss of an allyl radical via fragmentation. 
 
 
(±)-3-Methylhexa-1,5-dien-2-yl trifluoromethanesulfonate (19a). To a cooled solution 
of ethyl 2-methylacetoacetate (2.8 mL, 20 mmol) in THF (20 mL) at 0 ºC was added 
NaH (881 mg, 36.7 mmol of 60% in mineral oil) portion-wise. The resulting mixture was 
stirred at 0 ºC for 30 min, then allyl bromide (1.9 mL, 22 mmol) was then added 
dropwise and the solution was heated to reflux overnight. The solution was then cooled 
to rt, quenched with H2O (20 mL), and extracted with diethyl ether (3 x 20 mL). The 
combined organic layers were dried over anhydrous MgSO4, filtered, and concentrated 
in vacuo. The crude product was purified by column chromatography to afford 3.34 g 
(91%) of ethyl 2-acetyl-2-methylpent-4-enoate. Characterization data matched that that 
previously reported in the literature.[22]   
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 Decarboxylation of ethyl 2-acetyl-2-methylpent-4-enoate (1.5 g, 8.1 mmol) was 
accomplished using a general procedure reported by Šmit[23] for decarboxylation of β-
ketoesters except using pentanes instead of diethyl ether for the extraction. This 
procedure afforded 547 mg (60%) of 3-methylhex-5-en-2-one as a volatile oil. Note: 
Slow evaporation of pentanes was necessary to avoid loss of product. 1H NMR (500 
MHz, CDCl3)  5.72 (ddt, J = 17.1, 10.1, 7.0 Hz, 1H), 5.11 – 4.98 (m, 2H), 2.59 (h, J = 
7.0 Hz, 1H), 2.40 (dtt, J = 14.5, 6.6, 1.4 Hz, 1H), 2.18 – 2.06 (m, 4H), 1.10 (d, J = 7.0 
Hz, 3H). 
 The title compound was prepared using a procedure analogous to that employed 
for the synthesis of 3-phenylhexa-1,5-dien-2-yl trifluoromethanesulfonate, except using 
3-methylhex-5-en-2-one (1.49 g, 13.3 mmol) as substrate. This procedure afforded the 
title compound (1.99 g, 61%) as a volatile, clear oil. Note: Slow evaporation of the 
organic layer was necessary to avoid loss of product. 1H NMR (500 MHz, CDCl3)  5.72 
(ddt, J = 13.8, 9.9, 5.7 Hz, 1H), 5.17 – 5.04 (m, 3H), 4.92 (d, J = 3.9 Hz, 1H), 2.50 
(sextet, J = 6.8 Hz, 1H), 2.34 (dt, J = 19.1, 1.3 Hz, 1H), 2.15 (dt, J = 14.1, 7.6 Hz, 1H), 
1.15 (d, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3)  160.31, 134.68, 118.61 (q, J = 
317.9 Hz), 117.81, 102.90, 38.27, 37.92, 17.32; IR (film) 1416, 1205, 1140, 924 cm -1; 
MS (EI) 244.0374 (244.0381 calcd for C8H11F3O3S, M+). 
 
 
(±)-3-Phenylhexa-1,5-dien-2-yl trifluoromethanesulfonate (19b). To a stirred solution 
of methyl 2-phenylpent-4-enoate[15] (1.88 g, 9.87 mmol) in THF (49 mL) was added N,O-
dimethylhydroxylamine hydrochloride (2.02 g, 20.7 mmol). The resulting mixture was 
cooled to 0 ºC, then a solution of i-PrMgCl (19.8 mL, 29.5 mmol, 2M in THF) was added 
dropwise. The mixture was stirred at 0 ºC for 1 h, then the reaction was quenched with 
satd. NH4Cl (aq) (25 mL) and the resulting mixture was extracted with EtOAc (3 x 20 
mL). The combined organic layers were washed with brine, dried over anhydrous 
Na2SO4, filtered, and concentrated in vacuo to afford 1.9 g (88%) of the N-methoxy-N-
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methyl-2-phenylpent-4-enamide that was used without further purification. 
Characterization data matched that previously reported in the literature.[24]   
A flame-dried round bottom flask equipped with a stir-bar was cooled under a 
stream of N2 and charged with N-methoxy-N-methyl-2-phenylpent-4-enamide (1.9 g, 8.7 
mmol) and THF (17 mL). The resulting solution was cooled to 0 ºC in an ice-bath, then a 
solution of CH3MgBr (10.4 mL, 10.4 mmol, 1M in THF) was added dropwise. The 
mixture was stirred at 0 ºC for 1 h, then the reaction was quenched with satd. NH4Cl (aq) 
and the mixture was extracted with EtOAc (3 x 15 mL). The combined organic layers 
were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo to afford 1.46 g 
(97%) of the 3-phenylhex-5-en-2-one product that was used without further purification. 
Characterization data matched that that previously reported in the literature.[25] 
 The title compound was prepared using a procedure analogous to that employed 
for the synthesis of 6-allylcyclohex-1-en-1-yl trifluoromethanesulfonate, except using 3-
phenylhex-5-en-2-one (800 mg, 4.59 mmol) as the substrate and N-(2-
pyridyl)triflimide[11] (1.97g, 5.51 mmol) as the triflylating reagent. The crude product was 
purified by column chromatography to afford the title compound (974 mg, 69%) as a 
clear oil. 1H NMR (500 MHz, CDCl3) δ 7.35 (t, J = 7.3 Hz, 2H), 7.29 (t, J = 7.3 Hz, 1H), 
7.22 (d, J = 7.1 Hz, 2H), 5.66 (ddt, J = 17.0, 10.1, 6.8 Hz, 1H), 5.25 (d, J = 3.9 Hz, 1H), 
5.11 – 5.00 (m, 3H), 3.60 (t, J = 7.6 Hz, 1H), 2.70 (dt, J = 14.1, 6.9 Hz, 1H), 2.55 (dt, J = 
14.7, 7.5 Hz, 1H); 13C NMR (175 MHz, CDCl3)  158.22, 138.41, 134.65, 128.91, 
128.21, 127.79, 118.51 (q, J = 318.3 Hz), 117.60, 104.55, 50.16, 37.29; IR (film) 1416, 
1206, 1136 cm-1; MS (EI) 306.0551 (306.0538 calcd for C13H13F3O3S, M+).  
 
 
(±)-3-Methyl-3-phenylhexa-1,5-dien-2-yl trifluoromethanesulfonate (19c). A flame-
dried round bottom flask equipped with a stir bar was cooled under a stream of nitrogen 
and charged with 2-methyl-2-phenylpent-4-enoic acid[16] (1.2 g, 6.3 mmol) and Et2O (28 
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mL). The mixture was cooled to –78 ºC and a solution of MeLi (15.8 mmol, 1.6M in 
Et2O) was added dropwise. The resulting mixture was stirred for 1 h at –78 ºC, then was 
heated to reflux for 1 h. The mixture was then cooled to 0 ºC and quenched with H2O 
(20 mL). The aqueous phase was extracted with Et2O (3 x 20 mL), and the organic 
layers were combined, dried over anhydrous MgSO4, filtered, and concentrated in 
vacuo. The crude mixture was purified by column chromatography to afford 773 mg 
(65%) of 3-methyl-3-phenylhex-5-en-2-one as a clear oil. Characterization data matched 
that previously reported in the literature.[26] 
 The title compound was prepared using a procedure analogous to that employed 
for the synthesis 3,3-dimethylhexa-1,5-dien-2-yl trifluoromethanesulfonate except using 
3-methyl-3-phenylhex-5-en-2-one (773 mg, 4.1 mmol) as the substrate and N-(2-
pyridyl)triflimide[11] (1.77 g, 4.9 mmol) as triflylating agent. This procedure afforded 562 
mg (43%) of the title compound as a clear oil. 1H NMR (400 MHz, CDCl3)  7.34 (q, J = 
2.5 Hz, 4H), 7.29 – 7.24 (m, 1H), 5.56 (ddt, J = 17.1, 10.2, 7.1 Hz, 1H), 5.28 (d, J = 4.5 
Hz, 1H), 5.16 – 5.03 (m, 3H), 2.67 (ddd, J = 7.3, 4.2, 1.3 Hz, 2H); 13C NMR (100 MHz, 
CDCl3)  161.57, 142.08, 133.09, 128.62, 127.29, 126.67, 119.15, 102.24, 47.06, 42.86, 
23.87. The quartet associated with the CF3 group was not fully resolved; IR (film) 1413, 
1206 cm -1; MS (EI) 320.0691 (320.0694 calcd for C14H15F3O3S, M+).  
 
 
2-Allyl-3,4-dihydronaphthalen-1-yl trifluoromethanesulfonate (22a). Following a 
modification of a procedure reported by Murphy et. al.[12], to a stirring solution of n-BuLi 
(2.5 M in Hexanes) (8.9 mL, 22 mmol) diluted with THF (70 mL) at 0 ºC was added a 
solution of N'-3,4-dihydro-2H-naphthalenylidene-N,N-dimethylhydrazine[12] (3.8 g, 20 
mmol) in THF (20 mL) dropwise. The resulting solution was stirred for 1 h at 0 ºC, then a 
solution of allyl bromide (1.73 mL, 20 mmol) in THF (20 mL) was added dropwise at 0 
ºC. The reaction mixture was then warmed to rt and stirred for an additional 16 h. A 
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solution of 2N HCl (aq.) (110 mL) was then added and the resulting mixture was stirred 
vigorously for 48 h. The mixture was then extracted with EtOAc (30 mL x 3) and the 
combined organic layers were washed with brine, dried over anhydrous MgSO4, and 
concentrated in vacuo. The crude product was purified by column chromatography to 
afford 3.1 g (82%) of 2-allyl-3,4-dihydronaphthalen-1(2H)-one as a clear oil. 
Characterization data matched data previously reported in the literature for this 
compound.[12] 
The title compound was prepared following a procedure reported by Lin et. al.[27] 
for the synthesis of 2-methyl-3,4-dihydronaphthalen-1-yl trifluoromethanesulfonate 
except using 2-allyl-3,4-dihydronaphthalen-1(2H)-one in place of 2-methyl-1-tetralone 
as the substrate. This procedure afforded the title compound (1.32 g, 78%) as a clear 
oil. 1H NMR (700 MHz, CDCl3)  7.35 (d, J = 7.5 Hz, 1H), 7.30 – 7.19 (m, 2H), 7.15 (d, J 
= 7.3 Hz, 1H), 5.79 (ddt, J = 16.9, 10.1, 6.8 Hz, 1H), 5.20 (dq, J = 17.1, 1.5 Hz, 1H), 
5.17 (dt, J = 10.1, 1.3 Hz, 1H), 3.13 (d, J = 6.7 Hz, 2H), 2.83 (t, J = 8.0 Hz, 2H), 2.42 (t, 
J = 7.9 Hz, 2H); 13C NMR (175 MHz, CDCl3)  140.72, 135.75, 133.39, 131.22, 129.74, 
128.49, 127.49, 126.86, 121.47, 118.70 (q, J = 318.4 Hz), 118.36, 35.54, 27.39, 27.36; 
IR (film) 1206, 1138 cm-1; MS (EI) 318.0544 (318.0538 calcd for C14H13F3O3S, M+). 
  
 
2-Allyl-6-methoxy-3,4-dihydronaphthalen-1-yl trifluoromethanesulfonate (22b). 
The title compound was prepared using a procedure analogous to that employed for the 
synthesis of 2-allyl-3,4-dihydronaphthalen-1-yl trifluoromethanesulfonate except using 
6-methoxy-1-tetralone as the starting material. This procedure afforded the title 
compound (627 mg, 19% over 3 steps) as a clear oil. 1H NMR (400 MHz, CDCl3)  7.24 
(s, 1H), 6.79 – 6.62 (m, 2H), 5.76 (ddt, J = 16.8, 10.1, 6.7 Hz, 1H), 5.23 – 5.03 (m, 2H), 
3.79 (s, 3H), 3.07 (app. d, J = 8 Hz, 2H), 2.77 (t, J = 7.9 Hz, 2H), 2.36 (t, J = 7.9 Hz, 
2H); 13C NMR (100 MHz, CDCl3)  159.79, 140.60, 137.81, 133.67, 128.05, 122.92, 
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122.72, 120.29, 118.10, 113.94, 111.30, 55.45, 35.36, 27.82, 27.30. The quartet 
associated with the CF3 group was not fully resolved; IR (film) 1404, 1205, 1138 cm
-1; 
MS (ESI) 349.0720 (349.0716 calcd for C15H15F3O4S, M + H
+).  
 
Preparation and Characterization of Products 
General Procedure for Pd-Catalyzed Alkene Difunctionalization Reactions 
 A flame-dried Schlenk tube equipped with a stir bar was cooled under a stream 
of N2 and charged with Pd(OAc)2 (4 mol %), BrettPhos (6 mol %), and lithium tert-
butoxide (0.14 mmol, 1.4 equiv). The tube was purged with N2 (g) and a solution of the 
appropriate enol triflate (0.1 mmol, 1.0 equiv) in toluene (0.5 mL) was added via syringe 
with stirring. The appropriate nucleophile (0.12 mmol, 1.2 equiv) was then added neat 
via micro-syringe followed by toluene (0.5 mL) to wash the inside of the Schlenk tube so 
all reagents were in solution. The resulting mixture was heated to 95 oC for 16 h at 
which time the starting material had been completely consumed as judged by 1H NMR 
analysis of an aliquot removed from the reaction mixture. After cooling to room 
temperature, H2O (3 mL) was added. The aqueous layer was extracted with EtOAc (3 
mL x 3), the combined organic layers were dried over anhydrous Na2SO4, filtered, and 
concentrated in vacuo. The crude product was then purified by column chromatography 
on silica gel unless otherwise noted. In some instances, the product was protonated 
from silica gel chromatography. Thus, the neutral product was obtained by re-dissolving 
in DCM (5 mL) and washing with aqueous 1M NaOH (5 mL) in a separatory funnel. The 
organic layer was collected, dried with anhydrous Na2SO4, filtered through a cotton 
plug, and concentrated to afford the neutral desired product. 
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(±)-(2S*,3aR*)-4-(2,3,3a,4,5,6-Hexahydro-1H-inden-2-yl)morpholine (10a). The 
general procedure was used for the coupling of morpholine (10.4 µL, 0.12 mmol) and 6-
allylcyclohex-1-en-1-yl trifluoromethanesulfonate (27.0 mg, 0.1 mmol), except the 
reaction was conducted at 70 oC and 10 mol % BrettPhos was used. The crude product 
was purified by flash chromatography on silica gel to afford 17.3 mg (80%, >20:1 dr) of 
the title compound as a yellow oil. 1H NMR (400 MHz, CDCl3)  5.36 (t, J = 3.2 Hz, 1H), 
3.72 (t, J = 4.7 Hz, 4H), 2.65 – 2.54 (m, 2H), 2.47 (app. br s, 4H), 2.19 – 2.06 (m, 3H), 
2.02 – 1.91 (m, 3H), 1.80 – 1.73 (m, 1H), 1.42 (ttd, J = 13.8, 7.4, 4.1 Hz, 1H), 1.03 (dtd, 
J = 17.6, 11.3, 10.7 Hz, 2H); 13C NMR (175 MHz, CDCl3)  141.73, 118.30, 67.08, 
64.95, 52.69, 39.90, 38.13, 35.38, 28.86, 25.34, 22.46; IR (film) 1118, 1671 cm-1; MS 
(ESI) 208.1699 (208.1696 calcd for C13H21NO, M + H
+). 
 
 
Gram scale: (±)-(2S*,3aR*)-4-(2,3,3a,4,5,6-Hexahydro-1H-inden-2-yl)morpholine 
(10a). The general procedure was used for the gram scale coupling of morpholine (388 
µL, 4.44 mmol) and 6-allylcyclohex-1-en-1-yl trifluoromethanesulfonate (1.0 g, 3.7 
mmol) except the reaction was conducted at 70º C for 17 h. This procedure afforded 
594 mg (76%, >20:1 dr) of the title compound as a clear-yellow oil. Characterization 
data were identical to those reported above for the small (0.1 mmol) scale reaction. 
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(±)-(2S*,3aR*)-N,N-diethyl-2,3,3a,4,5,6-hexahydro-1H-inden-2-amine (10b). The 
general procedure was used for the coupling of diethylamine (12.4 µL, 0.12 mmol) and 
6-allylcyclohex-1-en-1-yl trifluoromethanesulfonate (26.5 mg, 0.1 mmol). The crude 
product was purified by flash chromatography on silica gel to afford 9.5 mg (50%, 2.7:1 
dr) of the title compound as a yellow oil. Data are for a diastereomeric mixture as the 
diastereomers were not readily separable: 1H NMR (700 MHz, CDCl3)  5.38 (app br s, 
0.27H), 5.37 (app. br s, 0.74H), 3.20 – 3.03 (m, 1 H), 2.66 (q, J = 7 Hz, 4H), 2.57 (dd, J 
= 17.0, 9.2 Hz, 1 H), 2.43 (app. br s, 0.3H), 2.38 (dd, J = 13.7, 6.8 Hz, 0.3H), 2.30 (m, 
0.32H), 2.25 – 2.14 (m, 1.62H), 2.09 (dt, J = 11.3, 6.1 Hz, 0.76H), 2.03 – 1.91 (m, 
3.79H), 1.80 – 1.73 (m, 1.15H), 1.60 – 1.54 (m, 0.3H), 1.54 – 1.38 (m, 1.72H), 1.16 – 
0.90 (m, 8.74H), 0.90 – 0.80 (m, 1.43H); 13C NMR (175 MHz, CDCl3)  118.13, 117.53, 
60.34, 60.28, 43.95, 43.83, 42.69, 39.89, 39.81, 38.08, 37.72, 37.26, 35.86, 35.29, 
30.14, 29.85, 29.09, 28.81, 25.34, 25.05, 22.73, 22.49, 11.02; IR (film) 1445, 1368 cm-1; 
MS (ESI) 194.1903 (194.1903 calcd for C13H24N
+, M + H+).  
 
 
(±)-(2S*,3aR*)-N-(Furan-2-ylmethyl)-2,3,3a,4,5,6-hexahydro-1H-inden-2-amine 
(10c). The general procedure was used for the coupling of furfurylamine (10.6 µL, 0.12 
mmol) and 6-allylcyclohex-1-en-1-yl trifluoromethanesulfonate (27.0 mg, 0.1 mmol), 
except 10 mol % BrettPhos was used. The crude product was purified by flash 
chromatography on silica gel to afford 14.8 mg (68%, >20:1 dr) of the title compound as 
a yellow oil. 1H NMR (500 MHz, CDCl3)  7.35 (app. br s, 1H), 6.30 (dd, J = 3.2, 1.8 Hz, 
1H), 6.19 (d, J = 3.1 Hz, 1H), 5.38 (app. br s, 1H), 3.79 (s, 2H), 3.17 (tt, J = 9.2, 6.4 Hz, 
1H), 2.65 (ddd, J = 15.2, 8.5, 3.0 Hz, 1H), 2.36 – 2.16 (m, 3H), 2.06 – 1.92 (m, 4H), 1.77 
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(dp, J = 10.9, 3.6 Hz, 1H), 1.43 (tdd, J = 13.2, 6.1, 2.9 Hz, 1H), 1.09 – 0.93 (m, 2H); 13C 
NMR (175 MHz, CDCl3)  153.81, 142.24, 141.94, 118.29, 110.27, 107.07, 56.51, 
44.92, 40.86, 39.81, 37.91, 29.09, 25.31, 22.55; IR (film) 1146, 1506 cm-1; MS (ESI) 
218.1544 (218.1539 calcd for C14H19NO, M + H
+). 
 
 
(±)-(2S*,3aR*)-N-benzyl-2,3,3a,4,5,6-hexahydro-1H-inden-2-amine (10d). The 
general procedure was used for the coupling of benzylamine (13.1 µL, 0.12 mmol) and 
6-allylcyclohex-1-en-1-yl trifluoromethanesulfonate (27.0 mg, 0.1 mmol). The crude 
product was purified by flash chromatography on silica gel to afford 19.2 mg (76%, 
>20:1 dr) of the title compound as a clear oil. 1H NMR (400 MHz, CDCl3)  7.32 (d, J = 
4.7 Hz, 4H), 7.28 – 7.21 (m, 1H), 5.39 (s, 1H), 3.78 (s, 2H), 3.20 (dt, J = 15.1, 7.6 Hz, 
1H), 2.68 (dd, J = 14.6, 7.8 Hz, 1H), 2.27 - 2.14 (m, 2H), 2.10 – 1.90 (m, 5H), 1.78 (ddd, 
J = 13.0, 7.0, 3.8 Hz, 1H), 1.43 (dtt, J = 18.9, 9.0, 4.4 Hz, 1H), 1.11 – 0.93 (m, 2H); 13C 
NMR (125 MHz, CDCl3)  142.51, 140.53, 128.53, 128.36, 127.06, 118.22, 56.80, 
52.66, 41.15, 39.83, 38.19, 29.18, 25.35, 22.59; IR (film) 1456, 1240, 1030 cm-1; MS 
(ESI) 228.1750 (228.1747 calcd for C16H21N, M + H
+).  
 
 
(±)-(2S*,3aR*)-N-benzyl-2,3,3a,4,5,6-hexahydro-1H-inden-2-amine hydrochloride 
(10d•HCl). In a vial charged with (±)-(2S*,3aR*)-N-benzyl-2,3,3a,4,5,6-hexahydro-1H-
inden-2-amine (0.075 mmol, 17.2 mg) was added HCl (2N in Et2O) (37.5 µL, 0.075 
mmol). The oil immediately solidified to a pale yellow solid (m.p. = 218–220 ºC). 1H NMR 
(400 MHz, CDCl3)  7.59 (d, J = 7.3 Hz, 2H), 7.42 – 7.29 (m, 3H), 5.42 (s, 1H), 3.98 (d, 
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J = 13.5 Hz, 1H), 3.92 (d, J = 13.5 Hz, 1H), 3.22 (dt, J = 15.1, 7.6 Hz, 1H), 2.70 (dd, J = 
15.9, 9.4 Hz, 1H), 2.55 (dd, J = 14.8, 8.7 Hz, 1H), 2.30 (dt, J = 11.8, 6.2 Hz, 1H), 2.17 – 
1.86 (m, 5H), 1.77 (dt, J = 13.3, 4.0 Hz, 1H), 1.55 – 1.33 (m, 3H), 1.11 (q, J = 13.3, 12.1 
Hz, 1H); 13C NMR (100 MHz, CDCl3)  138.60, 131.45, 130.37, 129.21, 129.13, 120.19, 
55.14, 50.06, 39.57, 37.20, 34.12, 28.18, 25.11, 22.20. 
 
 
(±)-(2S*,3aR*)-N-phenyl-2,3,3a,4,5,6-hexahydro-1H-inden-2-amine (10e). In a flame-
dried 4 mL vial equipped with a stir bar and Teflon screw cap was added 6-
allylcyclohex-1-en-1-yl trifluoromethanesulfonate (106.3 mg, 0.39 mmol), followed by 
Pd2(dba)3 (3.7 mg, 1 mol %), 2-(2-(diphenylphosphanyl)phenyl)-4,5-dihydrooxazole (5.3 
mg, 4 mol %), and lithium tert-butoxide (44.8 mg, 0.56 mmol). The mixture was pre-
stirred for 5 minutes at rt before aniline (43.7 µL, 0.48 mmol) was added neat. The vial 
was sealed and heated to 95 oC for 6 hr. The vial was cooled to rt and the crude product 
(4:1 dr) was purified by column chromatography to afford 62.9 mg (75%, 6:1 dr) of the 
title compound as a slightly yellow-tinted solid (m.p. = 52 ºC–54 ºC). The reported 1H 
and 13C NMR data are for the major diastereomer only. 1H NMR (400 MHz, CDCl3)  
7.19 (t, J = 7.7 Hz, 2H), 6.71 (t, J = 7.3 Hz, 1H), 6.62 (d, J = 7.8 Hz, 2H), 5.46 (s, 1H), 
3.88 (ddd, J = 14.7, 8.5, 6.0 Hz, 1H), 3.66 (br s, 1H), 2.99 – 2.83 (m, 1H), 2.45 (dt, J = 
12.5, 6.8 Hz, 1H), 2.39 – 2.21 (m, 1H), 2.12 – 1.98 (m, 4H), 1.84 (dp, J = 13.0, 3.7 Hz, 
1H), 1.49 (dtdd, J = 13.6, 11.2, 7.8, 2.6 Hz, 1H), 1.15 – 1.03 (m, 2H); 13C NMR (100 
MHz, CDCl3)  148.00, 142.22, 129.32, 118.61, 117.25, 113.45, 52.43, 41.13, 39.29, 
39.06, 29.34, 25.27, 22.53; IR (film) 1600, 1501 cm -1; MS (ESI) 214.1591 (214.1590 
calcd for C15H19N, M + H
+).  
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(±)-1-((6S*,7aR*)-1,3,5,6,7,7a-Hexahydrocyclopenta[c]pyran-6-yl)pyrrolidine (10f). 
The general procedure was used for the coupling of pyrrolidine (10 µL, 0.12 mmol) and 
3-allyl-3,6-dihydro-2H-pyran-4-yl trifluoromethanesulfonate (27.2 mg, 0.1 mmol). The 
crude product was purified by flash chromatography on silica gel to afford 11.2 mg 
(58%, >20:1 dr) of the title compound as a yellow oil. 1H NMR (500 MHz, CDCl3)  5.39 
(app. br s, 1H), 4.21 – 4.00 (m, 3H), 3.08 (t, J = 10.1 Hz, 1H), 2.69 – 2.60 (m, 2H), 2.53 
(app. br s, 5H), 2.35 – 2.22 (m, 1H), 2.01 (dt, J = 11.4, 5.2 Hz, 1H), 1.79 (app. br s, 4H), 
1.09 (q, J = 11.6 Hz, 1H); 13C NMR (175 MHz, CDCl3)  136.55, 119.00, 68.35, 65.13, 
64.34, 52.95, 38.50, 33.54, 32.82, 23.59; IR (film) 1653, 1080 cm-1; MS (ESI) 194.1538 
(194.1539 calcd for C12H19NO, M + H
+). 
 
 
(±)-(6S*,7aR*)-N-Cyclohexyl-1,3,5,6,7,7a-hexahydrocyclopenta[c]pyran-6-amine 
(10g). The general procedure was used for the coupling of cyclohexylamine (13.7 µL, 
0.12 mmol) and 3-allyl-3,6-dihydro-2H-pyran-4-yl trifluoromethanesulfonate (27.1 mg, 
0.1 mmol). The crude product was purified by flash chromatography on silica gel to 
afford 18.5 mg (84%, >20:1 dr) of the title compound as a yellow oil. 1H NMR (500 MHz, 
CDCl3)  5.39 (s, 1H), 4.22 – 4.01 (m, 3H), 3.41 (q, J = 7.8 Hz, 1H), 3.06 (t, J = 10.1 Hz, 
1H), 2.77 – 2.67 (m, 1H), 2.55 – 2.42 (m, 2H), 2.11 (dt, J = 12.3, 6.4 Hz, 1H), 2.07 – 
1.98 (m, 1H), 1.87 (app. br d, J = 12.4 Hz, 2H), 1.72 (app. br d, J = 9.6 Hz, 2H), 1.65 – 
1.58 (m, 1H), 1.33 – 1.19 (m, 3H), 1.18 – 1.11 (m, 1H), 1.10 – 1.0 (m, 2H), 0.86 (br p, J 
= 10.4 Hz, 1H); 13C NMR (175 MHz, CDCl3)  140.17, 116.95, 69.34, 65.27, 55.52, 
54.10, 38.70, 37.66, 36.51, 33.53, 26.08, 25.25; IR (film) 2926, 1456, 1120 cm-1; MS 
(ESI) 222.1855 (222.1852 calcd for C14H23NO, M + H
+). 
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(±)-(6S*,7aR*)-tert-Butyl 6-(cyclohexylamino)-1,3,5,6,7,7a-hexahydro-2H-
cyclopenta[c]pyridine-2-carboxylate (10h). The general procedure was used for the 
coupling of cyclohexylamine (13.8 µL, 0.12 mmol) and N-Boc-3-allyl-4-
{[(trifluoromethyl)sulfonyl}oxy}-3,6-dihydropyridine (37.1 mg, 0.1 mmol). The crude 
product was purified by flash chromatography on silica gel to afford 22.5 mg (70%, 
>20:1 dr) of the title compound as a white solid (m.p. = 44 ºC–50 ºC). The 
diastereomeric ratio was determined after cleavage of the -Boc group due to compound 
10h existing as a mixture of carbonyl rotamers in solution. 1H NMR and 13C NMR 
spectra were sufficiently broadened and complex due to rotamers: 1H NMR (500 MHz, 
CDCl3)  5.36 (d, J = 17.8 Hz, 1H), 4.47 – 4.02 (m, 2H), 3.57 – 3.45 (br m, 1H), 3.38 (p, 
J = 8.2 Hz, 1H), 2.70 (dd, J = 15.7, 7.5 Hz, 1H), 2.50 – 2.23 (m, 3H), 2.16 (dt, J = 12.0, 
6.1 Hz, 1H), 2.02 (dd, J = 15.5, 5.8 Hz, 1H), 1.86 (d, J = 11.1 Hz, 2H), 1.72 (d, J = 13.0 
Hz, 2H), 1.61 (d, J = 12.5 Hz, 1H), 1.45 (s, 9H), 1.29 – 1.19 (m, 3H), 1.14 (ddd, J = 
15.4, 9.1, 2.8 Hz, 1H), 1.04 (q, J = 10.1, 9.6 Hz, 2H), 0.92 (q, J = 11.0 Hz, 1H); 13C NMR 
(175 MHz, CDCl3)  114.71, 110.13, 79.57, 55.27, 54.49, 46.78, 45.52, 43.71, 39.08, 
38.21, 34.14, 28.63, 26.25, 25.30; IR (film) 1694, 1150 cm -1; MS (ESI) 321.2539 
(321.2537 calcd for C19H32N2O2, M + H
+).  
 
 
(±)-(6S*,7aR*)-N-Cyclohexyl-2,3,5,6,7,7a-hexahydro-1H-cyclopenta[c]pyridin-6-
amine (10h•H). A 20 mL scintillation vial equipped with a stir bar was charged with (±)-
(6S*,7aR*)-tert-butyl 6-(cyclohexylamino)-1,3,5,6,7,7a-hexahydro-2H-
cyclopenta[c]pyridine-2-carboxylate (22.5 mg, 0.07 mmol) in DCM (5 mL) and cooled to 
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0 oC in an ice bath. Trifluoroacetic acid (100 µL) was added over 5 min and the solution 
was allowed to warm to rt. After completion as judged by TLC, the crude mixture was 
concentrated in vacuo. The residue was dissolved in DCM (5 mL) and aqueous NaOH 
(1M) (3 mL). The aqueous layer was extracted using DCM (5 mL x 3), dried over 
anhydrous Na2SO4, filtered over a pad of cotton, and concentrated in vacuo to afford 
essentially quantitative yield of the desired product. The diastereomeric ratio was 
determined to be >20:1 by 1H NMR analysis of the sufficiently pure de-protected 
product. 1H NMR (400 MHz, CDCl3)  5.38 (s, 1H), 3.43 – 3.22 (m, 4H), 2.76 – 2.61 (m, 
1H), 2.48 (tt, J = 10.6, 3.8 Hz, 1H), 2.40 – 2.24 (m, 2H), 2.14 (dt, J = 12.2, 6.2 Hz, 1H), 
2.01 (ddt, J = 16.6, 7.3, 2.2 Hz, 1H), 1.92 – 1.81 (m, 3H), 1.71 (dt, J = 12.4, 3.9 Hz, 2H), 
1.66 – 1.54 (m, 1H), 1.30 – 0.98 (m, 6H), 0.89 (tt, J = 11.4, 8.1 Hz, 1H); 13C NMR (175 
MHz, CDCl3)  141.28, 116.67, 55.41, 54.42, 53.83, 48.25, 44.39, 39.19, 33.58, 28.64, 
26.10, 25.25. IR (film) 3360, 1031 cm-1; MS (ESI) 221.2014 (221.2012 calcd for 
C14H24N2, M + H
+).  
 
 
(±)-(6S*,7aR*)-tert-Butyl 6-([3,3-diphenylpropyl]amino)-1,3,5,6,7,7a-hexahydro-2H-
cyclopenta[c]pyridine-2-carboxylate (10i). The general procedure was used for the 
coupling of 3,3-diphenylpropylamine (24.8 µL, 0.12 mmol) and N-Boc-3-allyl-4-
{[(trifluoromethyl)sulfonyl]oxy}-3,6-dihydropyridine (37.2 mg, 0.1 mmol). The crude 
product was purified by flash chromatography on silica gel to afford 32.2 mg (74%, 
>20:1 dr) of the title compound as a yellow oil. The diastereomeric ratio was determined 
after deprotection of the -Boc group due to compound 10i existing as a mixture of 
carbonyl rotamers in solution. 1H NMR and 13C NMR spectra were sufficiently 
broadened and complex due to rotamers: 1H NMR (400 MHz, CDCl3)  7.36 – 7.10 (m, 
10H), 5.33 (br s, 1H), 4.45 – 4.05 (m, 3H), 3.99 (t, J = 7.8 Hz, 1H), 3.49 (br d, J = 13.1 
Hz, 1H), 3.16 (p, J = 9.0, 1H), 2.69 – 2.49 (m, 3H), 2.45 – 2.17 (m, 4H), 2.08 (dt, J = 
12.4, 6.4 Hz, 1H), 1.98 (dd, J = 16.4, 7.0 Hz, 1H), 1.46 (s, 9H), 0.88 (q, J = 11.3 Hz,1H); 
S23 
 
13C NMR (175 MHz, CDCl3)  144.84, 128.59, 127.88, 126.33, 115.22, 114.76, 79.57, 
57.79, 49.33, 47.09, 46.77, 45.52, 43.67, 43.09, 38.96, 37.86, 37.60, 36.30, 28.62; IR 
(film) 1681, 1153 cm -1; MS (ESI) 433.2860 (433.2850 calcd for C28H36N2O2, M + H
+).  
 
 
(±)-(6S*,7aR*)-N-(3,3-Diphenylpropyl)-2,3,5,6,7,7a-hexahydro-1H-
cyclopenta[c]pyridin-6-amine (10i•H). Using the procedure for the synthesis of N-
cyclohexyl-2,3,5,6,7,7a-hexahydro-1H-cyclopenta[c]pyridin-6-amine except using (±)-
(6S*,7aR*)-tert-butyl 6-[(3,3-diphenylpropyl)amino]-1,3,5,6,7,7a-hexahydro-2H-
cyclopenta[c]pyridine-2-carboxylate in place of (±)-(6S*,7aR*)-tert-butyl 6-
(cyclohexylamino)-1,3,5,6,7,7a-hexahydro-2H-cyclopenta[c]pyridine-2-carboxylate, the 
title compound was afforded in essentially quantitative yield. The diastereomeric ratio 
was determined to be >20:1 by 1H NMR analysis of the sufficiently pure de-protected 
product. 1H NMR (400 MHz, CDCl3)  7.28 – 7.20 (m, 8H), 7.16 (tt, J = 6.8, 2.0 Hz, 2H), 
5.36 (s, 1H), 3.99 (t, J = 7.8 Hz, 1H), 3.41 – 3.20 (m, 3H), 3.13 (tt, J = 8.9, 6.5 Hz, 1H), 
2.70 – 2.44 (m, 3H), 2.35 – 2.19 (m, 4H), 2.06 (td, J = 11.1, 10.5, 5.1 Hz, 1H), 1.94 (dd, 
J = 16.3, 6.2 Hz, 1H), 1.89 – 1.68 (m, 2H), 0.82 (q, J = 10.7 Hz, 1H); 13C NMR (175 
MHz, CDCl3)  144.68, 141.55, 128.63, 127.87, 126.38, 115.41, 57.14, 49.28, 47.62, 
46.93, 43.65, 38.25, 37.64, 35.85, 28.62.; IR (film) 3390, 1450 cm -1; MS (ESI) 333.2329 
(333.2325 calcd for C23H28N2, M + H
+). 
 
 
(±)-1-((2S*,3aR*)-3a-Methyl-2,3,3a,4,5,6-hexahydro-1H-inden-2-yl)pyrrolidine (10j). 
The general procedure was used for the coupling of pyrrolidine (10 µL, 0.12 mmol) and 
6-allyl-6-methylcyclohex-1-en-1-yl trifluoromethanesulfonate (28.4 mg, 0.1 mmol). The 
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crude product was purified by flash chromatography on silica gel to afford 19.4 mg 
(94%, >20:1 dr) of the title compound as a yellow oil. 1H NMR (400 MHz, CDCl3)  5.28 
(tt, J = 3.7, 1.9 Hz, 1H), 2.78 (tt, J = 9.7, 6.1 Hz, 1H), 2.72 – 2.61 (m, 1H), 2.47 (app. br 
s, 4H), 2.26 – 2.16 (m, 1H), 1.99 – 1.92 (m, 2H), 1.88 (dd, J = 11.7, 6.4 Hz, 1H), 1.77 
(app. br p, J = 3.7 Hz, 4H), 1.70 (dt, J = 12.2, 3.4 Hz, 1H), 1.65 – 1.58 (m, 2H), 1.32 – 
1.23 (m, 2H), 1.00 (s, 3H); 13C NMR (100 MHz, CDCl3)  145.33, 117.92, 62.29, 53.25, 
48.87, 40.83, 36.39, 36.19, 25.39, 25.10, 23.43, 18.78; IR (film) 2929, 1457 cm -1; MS 
(ESI) 206.1906 (206.1903 calcd for C14H23N, M + H
+).  
 
 
(±)-(2R*,3aR*)-3a-Methyl-2-(pyrrolidin-1-yl)-2,3,3a,6-tetrahydro-1H-inden-4-yl 
trifluoromethanesulfonate (10k). The general procedure was used for the coupling of 
pyrrolidine (20 µL, 0.24 mmol) and 2-allyl-2-methylcyclohexa-3,6-diene-1,3-diyl 
bis(trifluoromethanesulfonate)  (86.1 mg, 0.2 mmol), except RuPhos (6 mol %) ligand 
and 1.1 equiv of LiOtBu base were used and the reaction was conducted for 1 hr. The 
crude product was purified by flash chromatography on silica gel to afford 51.1 mg 
(73%, >20:1 dr) of the title compound as a red oil. 1H NMR (500 MHz, CDCl3)  5.69 
(dd, J = 5.0, 2.8 Hz, 1H), 5.34 (dd, J = 4.8, 2.2 Hz, 1H), 2.98 – 2.71 (m, 4H), 2.49 (br s, 
4H), 2.38 (dd, J = 16.8, 5.0 Hz, 1H), 2.00 (dd, J = 11.8, 6.6 Hz, 1H), 1.78 (m, 5H), 1.23 
(s, 3H); 13C NMR (100 MHz, CDCl3)  154.07, 144.16, 114.36, 113.15, 61.23, 53.03, 
44.83, 42.98, 35.00, 27.81, 24.22, 23.42; IR (film) 1413, 1210 cm -1; MS (ESI) 352.1198 
(352.1189 calcd for C15H20F3NO3S, M + H
+). 
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(±)-1-((1R*,2R*)-1-Methyl-2,3-dihydro-1H-inden-2-yl)pyrrolidine (12). The general 
procedure was used for the coupling of pyrrolidine (10 µL, 0.12 mmol) and 2-(but-3-en-
2-yl)phenyl trifluoromethanesulfonate (28 mg, 0.1 mmol). The crude product was 
purified by flash chromatography on silica gel to afford 10.9 mg (54%, 10:1 dr) of the 
title compound as a viscous oil. Data are for the major diastereomer. 1H NMR (500 
MHz, CDCl3)  7.20 – 7.13 (m, 4H), 3.23 (p, J = 6.9 Hz, 1H), 3.11 (dd, J = 15.7, 7.7 Hz, 
1H), 2.97 (dd, J = 15.7, 7.7 Hz, 1H), 2.84 (q, J = 7.5 Hz, 1H), 2.66 (br s, 4H), 1.82 (br s, 
4H), 1.39 (d, J = 6.9 Hz, 3H); 13C NMR (175 MHz, CDCl3)  146.53, 140.34, 126.88, 
126.86, 124.36, 123.61, 72.66, 52.35, 43.84, 36.69, 23.54, 20.21.; IR (film) 2962, 1148 
cm-1; MS (ESI) 202.1592 (202.1590 calcd for C14H19N, M + H
+).  
 
 
(±)-(2S*,3aR*)-4-(1,2,3,3a,4,5-Hexahydropentalen-2-yl)morpholine (14a). The 
general procedure was used for the coupling of morpholine (10.5 µL, 0.12 mmol) and 5-
allylcyclopent-1-en-1-yl trifluoromethanesulfonate (28.5 mg, 0.1 mmol), except 10 mol % 
BrettPhos was used. The crude product was purified by flash chromatography on silica 
gel to afford 14.5 mg (75%, >20:1 dr) of the title compound as a yellow oil. 1H NMR (500 
MHz, CDCl3)  5.25 (s, 1H), 3.73 (t, J = 4.8 Hz, 4H), 2.98 (p, J = 10 Hz, 1H), 2.84 (app. 
br s, 1H), 2.61 – 2.38 (m, 7H), 2.17 – 2.03 (m, 3H), 1.42 (p, J = 10 Hz, 1H), 1.02 (q, J = 
11.1 Hz, 1H); 13C NMR (175 MHz, CDCl3)  150.28, 119.10, 70.59, 66.89, 52.34, 50.30, 
37.19, 36.89, 31.93, 29.04; IR (film) 1119, 1266 cm-1; MS (ESI) 194.1542 (194.1539 
calcd for C12H19NO, M + H
+). 
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(±)-(2S*,3aR*)-N-Cyclohexyl-1,2,3,3a,4,5-hexahydropentalen-2-amine (14b). The 
general procedure was used for the coupling of cyclohexylamine (13.7 µL, 0.12 mmol) 
and 5-allylcyclopent-1-en-1-yl trifluoromethanesulfonate (28.5 mg, 0.1 mmol), except 10 
mol % BrettPhos was used. The crude product was purified by flash chromatography on 
silica gel to afford 17.8 mg (87%, >20:1 dr) of the title compound as a yellow oil. 1H 
NMR (500 MHz, CDCl3)  5.26 (app. br s, 1H), 3.64 (p, J = 9.4 Hz, 1H), 2.82 – 2.77 (m, 
1H), 2.64 – 2.38 (m, 4H), 2.25 (dt, J = 12.2, 6.4 Hz, 1H), 2.07 (dt, J = 13.0, 6.9 Hz, 1H), 
1.98 (app. br d, J = 15.6 Hz, 1H), 1.90 (app. br t, J = 12.2 Hz, 2H), 1.73 (br dt, J = 12.8, 
3.9 Hz, 2H), 1.62 (br dt, J = 12.7, 3.5 Hz, 1H), 1.40 (dq, J = 12.0, 9.4 Hz, 1H), 1.31 – 
1.05 (m, 6H), 0.99 – 0.80 (m, 1H); 13C NMR (175 MHz, CDCl3)  151.56, 118.68, 59.77, 
55.11, 50.35, 41.42, 37.03, 34.26, 33.98, 33.02, 32.19, 26.31, 25.34, 25.31; IR (film) 
1146, 1452 cm -1; MS (ESI) 206.1908 (206.1903 calcd for C14H23N, M + H
+).  
 
 
(±)-(2R*,3aS*)-Ethyl 2-(pyrrolidin-1-yl)-2,3,4,5-tetrahydropentalene-3a(1H)-
carboxylate (14c). The general procedure was used for the coupling of pyrrolidine (10 
µL, 0.12 mmol) and ethyl 1-allyl-2-{[(trifluoromethyl)sulfonyl]oxy}cyclopent-2-ene-1-
carboxylate (32.8 mg, 0.1 mmol). The crude product was purified by flash 
chromatography on silica gel to afford 19.1 mg (76%, >20:1 dr) of the title compound as 
a yellow oil. 1H NMR (500 MHz, CDCl3)  5.47 (app br s, 1H), 4.19 – 4.09 (m, 2H), 3.15 
(br p, J = 6.3 Hz, 1H), 2.85 – 2.77 (m, 1H), 2.57 – 2.44 (m, 7H), 2.39 (dd, J = 15.0, 10.0 
Hz, 1H), 2.25 (br dd, J = 11.7, 4Hz, 1H), 1.82 (dt, J = 9.1, 6.8 Hz, 1H), 1.77 (app. br s, 
4H), 1.39 (dd, J = 12.1, 9.7 Hz, 1H), 1.26 (t, J = 7.1 Hz, 3H); 13C NMR (175 MHz, 
CDCl3)  176.26, 149.15, 123.26, 68.24, 65.42, 60.65, 52.92, 42.98, 37.69, 36.96, 
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30.25, 23.40, 14.35; IR (film) 1719, 1152 cm -1; MS (ESI) 250.1808 (250.1802 calcd for 
C15H23NO2, M + H
+). 
 
 
(±)-(2R*,3aS*)-Ethyl 2-[(3,3-diphenylpropyl)amino]-2,3,4,5-tetrahydropentalene-
3a(1H)-carboxylate (14d). The general procedure was used for the coupling of 3,3-
diphenylpropylamine (24.8 µL, 0.12 mmol) and ethyl 1-allyl-2-
{[(trifluoromethyl)sulfonyl]oxy}cyclopent-2-ene-1-carboxylate (32.8 mg, 0.1 mmol). The 
crude product was purified by flash chromatography on silica gel to afford 22 mg (55%, 
>20:1 dr) of the title compound as a yellow oil. 1H NMR (500 MHz, CDCl3)  7.30 – 7.24 
(m, 8H), 7.18 (tt, J = 7.0, 1.8 Hz, 2H), 5.47 (app. br s, 1H), 4.15 – 4.08 (m, 2H), 4.00 (t, J 
= 7.8 Hz, 1H), 3.57 (dp, J = 11.4, 3.8 Hz, 1H), 2.85 – 2.75 (m, 1H), 2.61 (dd, J = 11.8, 
7.0 Hz, 1H), 2.57 – 2.49 (m, 4H), 2.44 (dd, J = 12.7, 6.8 Hz, 1H), 2.24 (qd, J = 7.9, 1.8 
Hz, 2H), 1.95 (br dd, J = 17.5, 3.6 Hz, 1H), 1.77 (dt, J = 12.8, 9.3 Hz, 1H), 1.24 (t, J = 
7.1 Hz, 3H), 1.10 (dd, J = 12.6, 8.1 Hz, 1H), 0.93 (app. br q, J = 7.4 Hz, 1H); 13C NMR 
(100 MHz, CDCl3)  176.12, 149.34, 144.88, 144.84, 128.59, 127.91, 127.89, 126.32, 
123.29, 65.05, 61.68, 60.64, 49.37, 46.93, 44.45, 37.91, 36.82, 36.24, 32.14, 14.33; IR 
(film) 1717, 697 cm -1; MS (ESI) 390.2436 (390.2428 calcd for C26H31NO2, M + H
+). 
 
 
(±)-(2S*,3aS*)-4-(3a-Allyl-1,2,3,3a,4,5-hexahydropentalen-2-yl)morpholine (14e). 
The general procedure was used for the coupling of morpholine (10.5 µL, 0.12 mmol) 
and 5,5-diallylcyclopent-1-en-1-yl trifluoromethanesulfonate (29.6 mg, 0,1 mmol), except 
10 mol % BrettPhos was used. The crude product was purified by flash chromatography 
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on silica gel to afford 21.7 mg (93%, >20:1 dr) of the title compound as a yellow oil. 1H 
NMR (700 MHz, CDCl3)  5.80 (dddd, J = 16.8, 10.1, 8.0, 6.4 Hz, 1H), 5.23 (app. br s, 
1H), 5.10 – 4.96 (m, 2H), 3.71 (t, J = 4.7 Hz, 4H), 3.11 (tt, J = 9.8, 6.3 Hz, 1H), 2.61 – 
2.55 (m, 1H), 2.53 – 2.33 (m, 6H), 2.18 (dd, J = 16.9, 5.5 Hz, 1H), 2.11 (dd, J = 13.9, 
6.6 Hz, 1H), 2.02 (dt, J = 12.1, 8.2 Hz, 2H), 1.94 (dd, J = 12.4, 6.9 Hz, 1H), 1.60 (dt, J = 
12.5, 9.5 Hz, 1H), 1.19 (dd, J = 11.8, 10.0 Hz, 1H); 13C NMR (175 MHz, CDCl3)  
152.81, 136.17, 119.32, 116.79, 68.73, 67.06, 58.80, 52.34, 41.25, 40.41, 37.10, 35.82, 
28.20; IR (film) 1636, 1266, 1118 cm-1; MS (ESI) 234.1859 (234.1852 calcd for 
C15H23NO, M + H
+).  
 
 
(±)-(2S*,3aS*)-3a-Allyl-N-cyclohexyl-1,2,3,3a,4,5-hexahydropentalen-2-amine (14f). 
The general procedure was used for the coupling of cyclohexylamine (13.7 µL, 0.12 
mmol) and 5,5-diallylcyclopent-1-en-1-yl trifluoromethanesulfonate (29.6 mg, 0.1 mmol), 
except 10 mol % BrettPhos was used. The crude product was purified by flash 
chromatography on silica gel to afford 24.8 mg (>95%, >20:1 dr) of the title compound 
as a yellow oil. 1H NMR (700 MHz, CDCl3)  5.80 (ddt, J = 17.2, 10.0, 7.2 Hz, 1H), 5.24 
(app. br s, 1H), 5.07 – 4.98 (m, 2H), 3.72 (tdd, J = 8.9, 6.7, 4.9 Hz, 1H), 2.60 – 2.52 (m, 
2H), 2.43 (tt, J = 10.7, 3.8 Hz, 1H), 2.36 (ddd, J = 13.1, 8.7, 3.1 Hz, 1H), 2.16 (dd, J = 
12.2, 6.8 Hz, 1H), 2.07 (dd, J = 13.8, 6.7 Hz, 1H), 2.01 (dd, J = 13.8, 7.8 Hz, 1H), 1.98 – 
1.90 (m, 2H), 1.86 (app. br d, J = 12.3 Hz, 1H), 1.80 (app. br d, J = 12.4 Hz, 1H), 1.71 
(app. br d, J = 13.2 Hz, 2H), 1.65 – 1.54 (m, 2H), 1.27 – 1.19 (m, 2H), 1.13 (qt, J = 12.7, 
3.6 Hz, 1H), 1.08 – 0.97 (m, 3H); 13C NMR (175 MHz, CDCl3)  153.59, 136.37, 119.19, 
116.62, 58.60, 57.66, 55.06, 45.91, 40.65, 37.26, 35.64, 34.29, 33.84, 32.20, 26.30, 
25.36, 25.28; IR (film) 1448, 1636 cm -1; MS (ESI) 246.2223 (246.2216 calcd for 
C17H27N, M + H
+). 
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(±)-(2S*,3aS*)-3a-Allyl-N-(3,3-diphenylpropyl)-1,2,3,3a,4,5-hexahydropentalen-2-
amine (14g). The general procedure was used for the coupling of 3,3-
diphenylpropylamine (24.8 µL, 0.12 mmol) and 5,5-diallylcyclopent-1-en-1-yl 
trifluoromethanesulfonate (29.6 mg, 0.1 mmol). The crude product was purified by flash 
chromatography on silica gel to afford 26.4 mg (94%, >20:1 dr) of the title compound as 
a yellow oil. 1H NMR (500 MHz, CDCl3)  7.33 – 7.23 (m, 8H), 7.19 (tt, J = 7.0, 1.8 Hz, 
2H), 5.80 (dddd, J = 16.9, 10.2, 7.8, 6.7 Hz, 1H), 5.26 (app br s, 1H), 5.08 – 4.99 (m, 
2H), 4.01 (t, J = 7.8 Hz, 1H), 3.50 (tdd, J = 8.6, 6.8, 4.6 Hz, 1H), 2.63 – 2.45 (m, 3H), 
2.29 (ddt, J = 15.8, 8.7, 2.7 Hz, 1H), 2.25 (tdd, J = 10.0, 6.7, 3.0 Hz, 2H), 2.13 (dd, J = 
12.4, 6.8 Hz, 1H), 2.07 (dd, J = 13.8, 6.7 Hz, 1H), 2.01 (dd, J = 13.8, 7.8 Hz, 1H), 1.98 – 
1.89 (m, 3H), 1.60 (dt, J = 12.4, 9.5 Hz, 1H), 1.08 (br s, 1 H), 1.00 (dd, J = 12.4, 8.3 Hz, 
1H); 13C NMR (125 MHz, CDCl3)  153.45, 144.94, 144.89, 136.30, 128.58, 127.92, 
127.89, 126.30, 119.32, 116.67, 61.14, 58.65, 49.40, 46.93, 45.36, 40.77, 37.34, 36.29, 
35.65, 31.58; IR (film) 1450, 698 cm -1; MS (ESI) 358.2530 (358.2529 calcd for C26H31N, 
M + H+).  
 
 
(±)-1-((1R*,2S*,3aR*)-1-Phenyl-1,2,3,3a,4,5-hexahydropentalen-2-yl)pyrrolidine 
(14h). The general procedure was used for the coupling of pyrrolidine (33.4 µL, 0.4 
mmol) and (E)-5-cinnamylcyclopent-1-en-1-yl trifluoromethanesulfonate (66.5 mg mg, 
0.2 mmol), except XPhos (5.7 mg, 6 mol %) was used as ligand an the reaction was 
conducted using 200 µL toluene solvent in a 4 mL vial equipped with a Teflon cap. The 
crude product was purified by flash chromatography on silica gel to afford 19 mg (37%, 
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5:1 dr) of the title compound as a viscous liquid. The reported 1H NMR data is for the 
major diastereomer only. The reported 13C NMR data is for the mixture of 
diastereomers. 1H NMR (500 MHz, Benzene-d6)  7.23 (d, J = 7.3 Hz, 2H), 7.17 (d, J = 
7.5 Hz, 2H), 7.07 (app. br t, J = 7.1 Hz, 1H), 5.20 (app. br s, 1H), 3.72 (d, J = 5.8 Hz, 
1H), 3.18 (ddd, J = 10.2, 7.2, 5.9 Hz, 1H), 3.05 (ddtt, J = 12.3, 9.3, 6.3, 3.2 Hz, 1H), 
2.60 – 2.22 (m, 6H), 2.21 – 1.99 (m, 2H), 1.60 – 1.39 (m, 5H), 1.32 (q, J = 11.1 Hz, 1H); 
13C NMR (125 MHz, CDCl3)  155.76, 146.50, 128.77, 128.44, 128.19, 127.82, 125.95, 
120.39, 119.87, 78.64, 75.66, 53.36, 52.95, 51.35, 50.35, 50.16, 48.07, 39.66, 37.19, 
37.03, 36.05, 34.59, 32.19, 29.85, 23.36, 23.31; IR (film) 1451, 700 cm -1; MS (ESI) 
254.1908 (254.1903 calcd for C18H23N, M + H
+).  
 
 
(±)-1-(3,3-Dimethyl-4-methylenecyclopentyl)pyrrolidine (18a). The general 
procedure was used for the coupling of pyrrolidine (10 µL, 0.12 mmol) and 3,3-
dimethylhexa-1,5-dien-2-yl trifluoromethanesulfonate (25.8 mg, 0.1 mmol), except the 
reaction was conducted for 1 hour. After cooling to rt, Et2O (5 mL) was added and the 
crude mixture was filtered through a cotton plug. The crude mixture was transferred into 
a separatory funnel and was extracted using aqueous 1M HCl (3 x 10 mL). The 
combined aqueous layers were placed back into a separatory funnel and treated with 4 
M NaOH until pH > 13. The basic aqueous layer was then extracted using DCM (3 x 10 
mL), the organic fractions were combined, dried over anhydrous Na2SO4, filtered 
through a cotton plug, and concentrated to afford 14.3 mg (80%) of the title compound 
as a clear oil. 1H NMR (500 MHz, CDCl3)  4.81 (s, 1H), 4.75 (s, 1H), 2.65 (ddd, J = 
15.4, 6.9, 1.5 Hz,1H), 2.60 – 2.47 (m, 5H), 2.41 (ddt, J = 15.5, 10.0, 2.9 Hz, 1H), 1.85 – 
1.74 (m, 5H), 1.56 (t, J = 11.3 Hz, 1H), 1.13 (s, 3H), 1.05 (s, 3H); 13C NMR (175 MHz, 
CDCl3)  159.95, 104.13, 63.10, 53.45, 48.16, 41.41, 40.38, 30.73, 29.64, 23.50; IR 
(film) 1344, 878 cm -1; MS (ESI) 180.1745 (180.1747 calcd for C12H21N, M + H
+).  
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(±)-4-(3,3-Dimethyl-4-methylenecyclopentyl)morpholine (18b). The general 
procedure was used for the coupling of morpholine (31.5 µL, 0.36 mmol) and 3,3-
dimethylhexa-1,5-dien-2-yl trifluoromethanesulfonate (77.8 mg, 0.3 mmol), except the 
reaction was conducted for 1 hour. The crude product was purified by liquid-liquid 
extraction as described for (±)-1-(3,3-dimethyl-4-methylenecyclopentyl)pyrrolidine to 
afford 33.8 mg (57%) of the title compound as a clear oil. 1H NMR (500 MHz, CDCl3)  
4.82 (s, 1H), 4.76 (s, 1H), 3.73 (br t, J = 4.7 Hz, 4H), 2.69 (dd, J = 15.3, 6.7 Hz, 1H), 
2.61 (app. p, J = 10.3 Hz, 1H), 2.48 (s, 4H), 2.40 – 2.29 (m, 1H), 1.83 (ddd, J = 11.9, 
6.2, 1.7 Hz, 1H), 1.48 (br t, J = 11.3 Hz, 1H), 1.14 (s, 3H), 1.05 (s, 3H); 13C NMR (175 
MHz, CDCl3)  159.11, 104.44, 66.97, 63.68, 52.70, 46.17, 41.33, 38.50, 30.67, 29.41; 
IR (film) 1453, 1118 cm -1; MS (ESI) 196.1695 (196.1696 calcd for C12H21NO, M + H
+).  
 
 
(±)-N-(3,3-Dimethyl-4-methylenecyclopentyl)cyclohexanamine (18c). The general 
procedure was used for the coupling of cyclohexylamine (13.7 µL, 0.12 mmol) and 3,3-
dimethylhexa-1,5-dien-2-yl trifluoromethanesulfonate (25.4 mg, 0.98 mmol), except the 
reaction was conducted for 6 h. The crude product was purified by column 
chromatography on silica gel to afford 12.3 mg (60%) of the title compound as a yellow-
tinted, clear oil. 1H NMR (400 MHz, CDCl3)  4.79 (app s, 1H), 4.75 (app s, 1H), 3.33 (tt, 
J = 9.7, 6.7 Hz, 1H), 2.75 (dd, J = 16.0, 7.2 Hz, 1H), 2.48 (tt, J = 10.6, 3.9 Hz, 1H), 2.16 
(ddt, J = 15.3, 9.4, 2.6 Hz, 1H), 1.93 – 1.82 (m, 3H), 1.72 (dt, J = 12.8, 3.9 Hz, 2H), 1.67 
– 1.55 (m, 2H), 1.39 – 1.00 (m, 12H); 13C NMR (100 MHz, CDCl3)  160.01, 104.08, 
55.34, 53.06, 49.57, 41.76, 41.19, 34.17, 34.01, 30.53, 29.57, 26.26, 25.34; IR (film) 
1149, 880 cm -1; MS (ESI) 208.2058 (208.206 calcd for C14H25N, M + H
+).  
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(±)-N-Benzyl-N,3,3-trimethyl-4-methylenecyclopentan-1-amine (18d). The general 
procedure was used for the coupling of N-benzylmethylamine (15.5 µL, 0.12 mmol) and 
3,3-dimethylhexa-1,5-dien-2-yl trifluoromethanesulfonate (26 mg, 0.1 mmol), except 
tris(pentafluorophenyl)phosphine (3.2 mg, 6 mol %) was used as ligand and the reaction 
was conducted for 6 h. The crude product was purified by column chromatography on 
silica gel to afford 13.2 mg (57%) of the title compound as a clear oil. 1H NMR (700 
MHz, CDCl3)  7.36 - 7.31 (m, 4H), 7.29 – 7.26 (m, 1H), 4.84 (s, 1H), 4.78 (s, 1H), 3.60 
(br s, 2H), 2.93 (br s, 1H), 2.77 (dd, J = 16.0, 7.5 Hz, 1H), 2.55 (br s, 1H), 2.17 (s, 3H), 
1.90 (dd, J = 12.1, 6.3 Hz, 1H), 1.68 (app. br s, 1H), 1.17 (s, 3H), 1.06 (s, 3H); 13C NMR 
(125 MHz, CDCl3)  159.29, 129.58, 129.10, 128.48, 127.40, 104.33, 62.82, 60.37, 
46.42, 41.49, 39.84, 38.75, 30.58, 29.36; IR (film) 1455, 697 cm -1; MS (ESI) 230.1909 
(230.1903 calcd for C16H23N, M + H
+). 
 
 
(±)-1-(3,3-Diallyl-4-methylenecyclopentyl)pyrrolidine (18e). The general procedure 
was used for the coupling of pyrrolidine (10 µL, 0.12 mmol) and 3,3-diallylhexa-1,5-dien-
2-yl trifluoromethanesulfonate (30.9 mg, 0.1 mmol), except RuPhos (2.8 mg, 6 mol %) 
was used as ligand and the reaction was conducted for 1.5 h. The crude product was 
purified by liquid-liquid extraction as described for (±)-1-(3,3-dimethyl-4-
methylenecyclopentyl)pyrrolidine to afford 22.4 mg (97%) of the title compound as a 
clear oil that was contaminated with ca 5% of an unidentified impurity as judged by 1H 
NMR analysis. 1H NMR (500 MHz, CDCl3)  5.84 – 5.72 (m, 2H), 5.07 – 4.95 (m, 5H), 
4.72 (d, J = 2.9 Hz, 1H), 2.59 (dd, J = 15.3, 6.6 Hz, 1H), 2.56 – 2.41 (m, 5H), 2.33 (ddt, 
J = 13.8, 10.4, 2.9 Hz, 1H), 2.25 – 2.05 (m, 4H), 1.82 (dd, J = 12.7, 6.5 Hz, 1H), 1.77 (s, 
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4H), 1.63 (dd, J = 12.5, 10.6 Hz, 1H); 13C NMR (100 MHz, CDCl3)  155.90, 135.58, 
135.37, 117.64, 117.30, 106.17, 63.10, 53.42, 47.60, 45.06, 44.89, 42.16, 41.22, 23.47; 
IR (film) 3062, 909 cm -1; MS (ESI) 232.2059 (232.206 calcd for C16H25N, M + H
+). 
 
 
(±)-1-((1S*,3R*)-3-Methyl-4-methylenecyclopentyl)pyrrolidine (20a). The general 
procedure was used for the coupling of pyrrolidine (20 µL, 0.24 mmol) and 3-
methylhexa-1,5-dien-2-yl trifluoromethanesulfonate (48.4 mg, 0.2 mmol), except CPhos 
(5.2 mg, 6 mol %) was used as ligand and the reaction was conducted for 1.5 h. The 
crude product was purified by liquid-liquid extraction as described for (±)-1-(3,3-
dimethyl-4-methylenecyclopentyl)pyrrolidine to afford 29 mg (88%,12:1 dr) of the title 
compound as a slightly yellow-tinted, clear oil. Characterization data are for the major 
diastereomer. This material contained 6% of an impurity that was determined to be 
CPhos as judged by 1H NMR analysis. 1H NMR (500 MHz, CDCl3)  4.84 (br s, 1H), 
4.74 (br s, 1H), 2.60 (dd, J = 15.9, 7.1, 1H), 2.56 – 2.38 (m, 6H), 2.31 (m, 1H), 2.09 (dt, 
J = 11.6, 5.75 Hz, 1H), 1.77 (p, J = 3.4 Hz, 4H), 1.22 (q, J = 11.6 Hz, 1H), 1.09 (d, J = 6.7 
Hz, 3H); 13C NMR (100 MHz, CDCl3)  155.58, 104.85, 64.30, 53.41, 41.84, 39.79, 
37.55, 23.47, 18.81; IR (film) 1656, 1457 cm-1; MS (ESI) 166.1588 (16.159 calcd for 
C11H19N, M + H
+). 
 
 
(±)-1-((1S*,3R*)-3-Methyl-4-methylenecyclopentyl)piperidine (20b). The general 
procedure was used for the coupling of piperidine (11.9 µL, 0.12 mmol) and 3-
methylhexa-1,5-dien-2-yl trifluoromethanesulfonate (24.2 mg, 0.1 mmol), except CPhos 
(2.6 mg, 6 mol %) was used as ligand and the reaction was conducted for 1.5 h. The 
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crude product was purified by liquid-liquid extraction as described for (±)-1-(3,3-
dimethyl-4-methylenecyclopentyl)pyrrolidine to afford 14.9 mg (98%, 6:1 dr) of the title 
compound as a slightly yellow-tinted, clear oil. Characterization data are for the major 
diastereomer. This material contained 3.5% of an impurity that was determined to be 
CPhos as judged by 1H NMR analysis.  1H NMR (500 MHz, CDCl3)  4.83 (br s, 1H), 
4.75 (br s, 1H), 2.65 (ddd, J = 16.1, 7.4, 2.0 Hz, 1H), 2.53 – 2.35 (m, 5H), 2.28 (ddq, J = 
15.2, 9.8, 2.6 Hz, 1H), 2.14 (dt, J = 11.6, 5.8 Hz, 1H), 1.59 (p, J = 6.0 Hz, 5H), 1.43 (m, 
J = 9.4, 5.8 Hz, 2H), 1.18 (q, J = 11.5 Hz, 1H), 1.09 (d, J = 6.6 Hz, 3H); 13C NMR (100 
MHz, CDCl3)  155.31, 104.76, 65.09, 53.28, 40.04, 38.34, 37.48, 25.97, 24.53, 18.59; 
IR (film) 2929, 880, 732 cm -1; MS (ESI) 180.1745 (180.1747 calcd for C12H21N, M + 
H+).  
 
 
(±)-(1S*,4R*)-3-Methylene-N-octyl-4-phenylcyclopentan-1-amine (20c). The general 
procedure was used for the coupling of octylamine (19.8 µL, 0.12 mmol) and and 3-
phenylhexa-1,5-dien-2-yl trifluoromethanesulfonate (30.9 mg, 0.1 mmol), except 
RuPhos (2.8 mg, 6 mol %) was used as ligand and the reaction was conducted for 6 h. 
The crude product was purified by column chromatography on silica gel to afford 20.7 
mg (72%, 4:1 dr) of the title compound as a yellow-tinted, oil. 1H NMR data are for the 
major diastereomer and 13C NMR data are for the mixture. 1H NMR (700 MHz, CDCl3)  
7.28 (t, J = 7.5 Hz, 2H), 7.24 – 7.16 (m, 3H), 4.96 (app. s, 1H), 4.55 (app. s, 1H), 3.58 
(ddd, J = 12.5, 7.3, 2.8 Hz, 1H), 3.51 (ddd, J = 17.5, 10.4, 6.6 Hz, 1H), 3.00 (dd, J = 
16.4, 7.7 Hz, 1H), 2.96 – 2.87 (m, 2H), 2.82 (m, 1H), 2.59 (dt, J = 12.6, 6.7 Hz, 1H), 
2.15 (q, 1H), 1.81 – 1.73 (m, 2H), 1.34 – 1.17 (m, 10H), 0.87 (t, J = 7.1 Hz, 3H); 13C 
NMR (175 MHz, CDCl3)  150.13, 142.31, 128.67, 128.65, 128.45, 128.10, 126.86, 
126.66, 110.73, 110.40, 57.43, 57.12, 49.36, 47.70, 47.65, 47.55, 39.34, 37.18, 31.82, 
29.24, 29.23, 29.17, 29.16, 27.00, 26.95, 26.87, 22.73, 14.20; IR (film) 1236, 1028, 638 
cm -1; MS (ESI) 286.2536 (286.2529 calcd for C20H31N, M + H
+).  
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(±)-1-((1S*,4R*)-3-Methylene-4-phenylcyclopentyl)pyrrolidine (20d). The general 
procedure was used for the coupling of pyrrolidine (10 µL, 0.12 mmol) and 3-
phenylhexa-1,5-dien-2-yl trifluoromethanesulfonate (30.9 mg, 0.1 mmol), except 
RuPhos (2.8 mg, 6 mol %) was used as ligand and the reaction was conducted for 1.5 
h. The crude product was purified by liquid-liquid extraction as described for (±)-1-(3,3-
dimethyl-4-methylenecyclopentyl)pyrrolidine to afford 22.6 mg (>98%, >20:1 dr) of the 
title compound as a yellow-tinted, clear oil. 1H NMR (500 MHz, CDCl3)  7.29 (t, J = 7.5 
Hz, 2H), 7.24 – 7.17 (m, 3H), 4.96 (s, 1H), 4.50 (s, 1H), 3.61 (ddt, J = 12.6, 7.1, 2.8 Hz, 
1H), 2.79 (dd, J = 15.3, 2.0 Hz, 1H), 2.66 – 2.49 (m, 6H), 2.35 (p, J = 11.6 Hz, 1H), 1.89 
– 1.75 (m, 5H); 13C NMR (125 MHz, CDCl3)  154.25, 144.16, 128.52, 128.47, 126.34, 
108.37, 64.51, 53.54, 50.13, 42.73, 40.42, 23.57, 23.52; IR (film) 2778, 697 cm -1; MS 
(ESI) 228.1746 (228.1747 calcd for C16H21N, M + H
+). 
 
 
(±)-1-((1R*,3R*)-3-Methyl-4-methylene-3-phenylcyclopentyl)pyrrolidine (20e). The 
general procedure was used for the coupling of pyrrolidine (10 µL, 0.12 mmol) and 3-
methyl-3-phenylhexa-1,5-dien-2-yl trifluoromethanesulfonate (32 mg, 0.1 mmol), except 
RuPhos (2.8 mg, 6 mol %) was used as ligand and the reaction was conducted for 1.5 
h. The crude product was purified by column chromatography on silica gel to afford 19.4 
mg (80%, >20:1 dr) of the title compound as a clear oil. 1H NMR (400 MHz, CDCl3)  
7.40 (d, J = 7.8 Hz, 2H), 7.27 (br t (incidental overlap with CDCl3), J = 9.7, 2H), 7.15 (t, J 
= 7.3 Hz, 1H), 5.01 (s, 1H), 4.60 (s, 1H), 2.83 (dd, J = 14.7, 5.9 Hz, 1H), 2.74 - 2.64 (m, 
1H), 2.64 – 2.47 (m, 5H), 2.17 – 2.02 (m, 2H), 1.79 (br s, 4H), 1.49 (s, 3H); 13C NMR 
(100 MHz, CDCl3)  159.63, 149.82, 128.04, 126.72, 125.72, 108.08, 63.67, 53.55, 
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51.19, 49.62, 42.07, 29.01, 23.51; IR (film) 1344, 697 cm -1; MS (ESI) 242.1903 
(242.1903 calcd for C17H23N, M + H
+). 
 
Asymmetric Pd-Catalyzed Alkene Carboamination Reactions 
The absolute configuration was assigned based on analogy with our previous results[4]  
which utilized identical reagents (Pd(OAc)2, (S)-
tBuPhox ligand, LiOtBu base, toluene, 
pyrrolidine nucleophile, 95 ºC), except the structurally similar starting material 2-
allylnaphthalen-1-yl trifluoromethanesulfonate was used in place of 2-allyl-3,4-
dihydronaphthalen-1-yl trifluoromethanesulfonate. 
 
 
(+)-(S)-1-(2,3,4,5-Tetrahydro-1H-cyclopenta[a]naphthalen-2-yl)pyrrolidine (23a). 
The general procedure was used for the coupling of pyrrolidine (10 µL, 0.12 mmol) and 
2-allyl-3,4-dihydronaphthalen-1-yl trifluoromethanesulfonate (31.8 mg, 0.1 mmol), 
except (S)-tBuPHOX was used as ligand. The crude product was purified by flash 
chromatography on silica gel to afford 18.2 mg (76%) of the title compound as 
crystalline yellow needles (m.p. = 80 ºC - 83 ºC). This material was judged to be 98:2 er 
by chiral HPLC analysis (Chiralcel OD-H, 0.46 cm x 15 cm, 1% IPA/Hexanes (+0.1% 
diethylamine), 0.5 mL/min, λ 275 nm, RT = 7.6 min and 10.6 min, [α]D
26 +50.2 (c 1.03, 
CH2Cl2). 
1H NMR (400 MHz, CDCl3)  7.18 – 7.05 (m, 3H), 7.00 (d, J = 7.4 Hz, 1H), 
3.13 (p, J = 7.6 Hz, 1H), 2.91 – 2.76 (m, 3H), 2.68 – 2.49 (m, 7H), 2.30 (t, J = 8.0 Hz, 
1H), 1.83 (app. br p, J = 3.4 Hz, 4H); 13C NMR (100 MHz, CDCl3)  138.02, 135.16, 
133.71, 132.41, 127.41, 126.44, 126.20, 122.34, 64.20, 52.80, 41.87, 36.55, 28.62, 
24.39, 23.64.; IR (film) 1653, 1341 cm-1; MS (ESI) 240.1749 (240.1747 calcd for 
C17H21N, M + H
+).  
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(+)-(S)-4-(2,3,4,5-Tetrahydro-1H-cyclopenta[a]naphthalen-2-yl)morpholine (23b). 
The general procedure was used for the coupling of morpholine (10.5 µL, 0.12 mmol) 
and 2-allyl-3,4-dihydronaphthalen-1-yl trifluoromethanesulfonate (31.8 mg, 0.1 mmol), 
except (S)-tBuPHOX was used as ligand. The crude product was purified by flash 
chromatography on silica gel to afford 19.1 mg (75%) of the title compound as an 
orange oil. This material was judged to be 94:6 er by chiral HPLC analysis (Chiralcel 
OD-H, 0.46 cm x 15 cm, 1% IPA/Hexanes (+0.1% diethylamine), 0.5 mL/min, λ 285 nm, 
RT = 14.1 min and 26.3 min, [α]D
26 +23.2 (c 1.3, CH2Cl2). 
1H NMR (500 MHz, CDCl3)  
7.18 – 7.07 (m, 3H), 6.99 (d, J = 7.4 Hz, 1H), 3.77 (br t, J = 4.7 Hz, 4H), 3.23 (p, J = 7.5 
Hz, 1H), 2.92 – 2.76 (m, 3H), 2.65 – 2.46 (m, 7H), 2.30 (br t, J = 7.6 Hz, 2H); 13C NMR 
(175 MHz, CDCl3)  137.61, 135.12, 133.35, 132.21, 127.49, 126.50, 126.41, 122.32, 
66.83, 65.26, 51.53, 39.63, 34.50, 28.56, 24.28; IR (film) 1653, 1264, 1117 cm-1; MS 
(ESI) 256.1700 (256.1696 calcd from C17H21NO, M + H
+).  
 
 
(+)-(S)-N-Cyclohexyl-2,3,4,5-tetrahydro-1H-cyclopenta[a]naphthalen-2-amine (23c). 
The general procedure was used for the coupling of cyclohexylamine (13.7 µL, 0.12 
mmol) and 2-allyl-3,4-dihydronaphthalen-1-yl trifluoromethanesulfonate (31.8 mg, 0.1 
mmol), except (S)-tBuPHOX was used as ligand. The crude product was purified by 
flash chromatography on silica gel to afford 11.7 mg (44%) of the title compound as an 
orange oil. This material was judged to be 98.5:1.5 er by chiral HPLC analysis (Chiralcel 
OD-H, 0.46 cm x 15 cm, 1% IPA/Hexanes (+0.1% diethylamine), 0.5 mL/min, λ 275 nm, 
RT = 9.2 min and 10.3 min, [α]D
26 +17.4 (c 0.81, CH2Cl2). MS (ESI) 268.2059 (268.2060 
calcd for C19H25N, M + H
+). 1H NMR (400 MHz, CDCl3)  7.18 – 7.05 (m, 3H), 6.98 (d, J 
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= 7.4 Hz, 1H), 3.80 (tt, J = 8.0, 5.6 Hz, 1H), 2.94 (dd, J = 15.4, 7.8 Hz, 1H), 2.87 (t, J = 
8.2 Hz, 2H), 2.77 (dd, J = 16.9, 7.7 Hz, 1H), 2.58 (tt, J = 10.5, 3.6 Hz, 1H), 2.44 (dp, J = 
15.4, 2.7 Hz, 1H), 2.37 – 2.25 (m, 3H), 1.99 – 1.87 (m, 2H), 1.76 (d, J = 12.6 Hz, 2H), 
1.64 (d, J = 12.4 Hz, 1H), 1.36 – 1.05 (m, 6H); 13C NMR (100 MHz, CDCl3)  137.90, 
135.13, 133.82, 132.18, 127.38, 126.41, 126.16, 122.35, 55.03, 54.14, 44.33, 38.94, 
34.04, 33.93, 28.59, 26.31, 25.37, 24.49; IR (film) 2922, 1448 cm-1; MS (ESI) 268.2062 
(268.2060 calcd for C19H25N, M + H
+).  
 
 
(+)-(S)-N-Octyl-2,3,4,5-tetrahydro-1H-cyclopenta[a]naphthalen-2-amine (23d). The 
general procedure was used for the coupling of octylamine (19.8 µL, 0.12 mmol) and 2-
allyl-3,4-dihydronaphthalen-1-yl trifluoromethanesulfonate (31.8 mg, 0.1 mmol), except 
(S)-tBuPHOX was used as ligand. The crude product was purified by flash 
chromatography on silica gel to afford 8.1 mg (28%) of the title compound as a yellow 
viscous oil. This material was judged to be 98.5:1.5 er by chiral HPLC analysis 
(Chiralcel OD-H, 0.46 cm x 15 cm, 1% IPA/Hexanes (+0.1% diethylamine), 0.5 mL/min, 
λ 275 nm, RT = 9.9 min and 12.3 min, [α]D
26 +92.4 (c 0.62, CH2Cl2). 
1H NMR (700 MHz, 
CDCl3)  7.20 – 7.06 (m, 3H), 6.98 (d, J = 7.5 Hz, 1H), 3.62 (ddd, J = 12.8, 7.6, 5.1 Hz, 
1H), 2.93 (dd, J = 15.8, 7.7 Hz, 1H), 2.87 (t, J = 8.3 Hz, 2H), 2.77 (dd, J = 17.0, 7.7 Hz, 
1H), 2.65 (tt, J = 11.3, 5.6 Hz, 2H), 2.46 (app. br d, J = 17.2 Hz, 1H), 2.37 - 2.26 (m, 
3H), 1.52 (p, J = 7.3 Hz, 2H), 1.39 – 1.20 (m, 10H), 0.88 (t, J = 7.0 Hz, 3H); 13C NMR 
(175 MHz, CDCl3)  137.91, 135.17, 133.86, 132.21, 127.39, 126.42, 126.17, 122.37, 
57.58, 48.45, 43.94, 38.59, 31.99, 30.56, 29.71, 29.43, 28.62, 27.69, 24.49, 22.82, 
14.25; IR (film) 2923, 1457 cm-1; MS (ESI) 298.2530 (298.2529 calcd for C21H31N, M + 
H+).  
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(+)-(S)-4-(7-Methoxy-2,3,4,5-tetrahydro-1H-cyclopenta[a]naphthalen-2-
yl)morpholine (23e). The general procedure was used for the coupling of morpholine 
(10.5 µL, 0.12 mmol) and 2-allyl-6-methoxy-3,4-dihydronaphthalen-1-yl 
trifluoromethanesulfonate (34.8 mg, 0.1 mmol), except (S)-tBuPHOX was used as 
ligand. The crude product was purified by flash chromatography on silica gel to afford 
17.5 mg (61%) of the title compound as an orange viscous oil. This material was judged 
to be 93:7 er by chiral HPLC analysis (Chiralcel OD-H, 0.46 cm x 15 cm, 1% 
IPA/Hexanes (+0.1% diethylamine), 0.5 mL/min, λ 275 nm, RT = 17.2 min and 21.9 min, 
[α]D
26  +20.4 (c 1.3, CH2Cl2). 
1H NMR (500 MHz, CDCl3)  6.91 (d, J = 8.2 Hz, 1H), 6.71 
(d, J = 2.5 Hz, 1H), 6.68 (dd, J = 8.2, 2.7 Hz, 1H), 3.79 (s, 3H), 3.76 (br t, J = 4.7 Hz, 
4H),  3.22 (p, J = 7.4 Hz, 1H), 2.88 – 2.73 (m, 3H), 2.62 – 2.45 (m, 7H), 2.27 (t, J = 7.1 
Hz, 2H); 13C NMR (100 MHz, CDCl3)  158.30, 136.98, 134.84, 131.74, 126.76, 123.24, 
114.20, 110.70, 67.09, 65.28, 55.40, 51.69, 39.69, 34.78, 29.05, 24.21; IR (film) 1606, 
1243, 1117 cm-1; MS (ESI) 286.1803 (286.1802 calcd for C18H23NO2, M + H
+).  
 
 
(+)-(S)-1-(7-Methoxy-2,3,4,5-tetrahydro-1H-cyclopenta[a]naphthalen-2-
yl)pyrrolidine (23f). The general procedure was used for the coupling of pyrolidine (10 
µL, 0.12 mmol) and 2-allyl-6-methoxy-3,4-dihydronaphthalen-1-yl 
trifluoromethanesulfonate (34.8 mg, 0.1 mmol), except (S)-tBuPHOX was used as 
ligand. The crude product was purified by flash chromatography on silica gel to afford 
16.8 mg (62%) of the title compound as an orange oil. This material was judged to be 
98:2 er by chiral HPLC analysis (Chiralcel OD-H, 0.46 cm x 15 cm, 1% IPA/Hexanes 
(+0.1% diethylamine), 0.5 mL/min, λ 275 nm, RT = 9.4 min and 10.4 min, [α]D
26 +30.1 (c 
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1.1, CH2Cl2). 
1H NMR (500 MHz, CDCl3)  6.92 (d, J = 8.2 Hz, 1H), 6.71 (br s, 1H), 6.68 
(dd, J = 8.2, 2.6 Hz, 1H), 3.78 (s, 3H), 3.16 (p, J = 7.4 Hz, 1H), 2.88 – 2.74 (m, 3H), 
2.67 – 2.49 (m, 7H), 2.27 (br t, J = 8.1 Hz, 2H), 1.84 (br p, J = 3.1 Hz, 4H); 13C NMR 
(100 MHz, CDCl3)  158.20, 137.00, 135.15, 131.92, 127.03, 123.25, 114.14, 110.66, 
64.27, 55.40, 52.81, 41.78, 36.72, 29.08, 24.29, 23.63; IR (film) 1500, 1244 cm-1; MS 
(ESI) 270.1857 (270.1852 calcd for C18H23NO, M + H
+).  
 
 
(+)-(S)-N-Benzyl-7-methoxy-N-methyl-2,3,4,5-tetrahydro-1H-
cyclopenta[a]naphthalen-2-amine (23g). The general procedure was used for the 
coupling of N-benzylmethylamine (15.5 µL, 0.12 mmol) and 2-allyl-6-methoxy-3,4-
dihydronaphthalen-1-yl trifluoromethanesulfonate (34.8 mg, 0.1 mmol), except (S)-
tBuPHOX was used as ligand. The crude product was purified by flash chromatography 
on silica gel to afford 15.7 mg (50%) of the title compound as an orange oil. This 
material was judged to be 85:15 er by chiral HPLC analysis (Chiralcel OD-H, 0.46 cm x 
15 cm, 1% IPA/Hexanes (+0.1% diethylamine), 0.5 mL/min, λ 275 nm, RT = 9.2 min and 
10.4 min, [α]D
26  +12.0 (c 1.0, CH2Cl2).
 1H NMR (500 MHz, CDCl3)  7.37 (d, J = 7.4 Hz, 
2H), 7.32 (d, J = 7.6 Hz, 2H), 7.27 (m (incidental overlap with CDCl3), 1H), 6.95 (d, J = 
8.2 Hz, 1H), 6.72 (s, 1H), 6.70 (dd, J = 8.2, 2.2 Hz, 1H), 3.80 (s, 3H), 3.62 – 3.51 (m, 
3H), 2.89 – 2.76 (m, 3H), 2.75 – 2.56 (m, 3H), 2.30 (br s, 2H), 2.20 (s, 3H). 13C NMR 
(125 MHz, CDCl3)  158.29, 136.99, 135.24, 131.99, 129.38, 129.28, 128.43, 127.21, 
126.87, 123.33, 114.21, 110.71, 63.64, 59.30, 55.42, 39.59, 38.89, 34.47, 29.08, 24.25; 
IR (film) 1499, 1244 cm-1; MS (ESI) 320.2013 (320.2009 calcd for C22H25NO, M + H
+).  
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(S)-N-(-1-Phenylethyl)-2,3,4,5-tetrahydro-1H-cyclopenta[a]naphthalen-2-amine 
(24). The general procedure was used for the coupling of (S)-(−)-α-methylbenzylamine 
(15.5 µL, 0.12 mmol) and 2-allyl-3,4-dihydronaphthalen-1-yl trifluoromethanesulfonate 
(31.8 mg, 0.1 mmol) to afford 8.2 mg (29%) of the title product as an inseparable 1.2:1 
mixture of diastereomers as a clear oil. This material was judged to be 99.2:0.8 er for 
the major diastereomer and 99.5:0.5 er for the minor diastereomer by chiral HPLC 
analysis (Chiralcel AD-H, 25 cm x 4.6 mm, 1% IPA/Hexanes (+0.1% diethylamine), 1.0 
mL/min, λ 275 nm, RT = 6.385 min and 9.491 min for the major diastereomer and 6.739 
min and 8.943 min for the minor diastereomer). Characterization data are for the 
mixture of diastereomers: 1H NMR (700 MHz, CD3OD)  7.42 (t, J = 6.8 Hz, 2H), 7.38 
(dt, J = 7.6, 4.0 Hz, 2H), 7.29 (td, J = 7.3, 4.5 Hz, 1H), 7.16 – 7.09 (m, 2H), 7.06 (q, J = 
7.4 Hz, 1H), 7.00 (d, J = 7.4 Hz, 0.5H), 6.92 (d, J = 7.4 Hz, 0.5H), 3.97 (q, J = 6.7 Hz, 
0.45H), 3.93 (q, J = 6.7 Hz, 0.53H), 3.42 (h, J = 6.5 Hz, 1H), 2.87 – 2.76 (m, 3H), 2.70 – 
2.55 (m, 1.5H), 2.46 (td, J = 21.0, 20.3, 5.4 Hz, 1H), 2.36 – 2.24 (m, 2.5H), 1.45 (d, J = 
2.5 Hz, 145H), 1.44 (d, J = 2.5 Hz, 1.55H); 13C NMR (100 MHz, CDCl3)145.78, 
138.04, 137.78, 135.16, 135.12, 133.75, 132.26, 132.10, 128.60, 128.60, 128.59, 
127.40, 127.37, 127.11, 126.90, 126.88, 126.42, 126.17, 122.34, 122.32, 56.51, 56.42, 
55.03, 54.91, 44.36, 43.52, 39.03, 28.60, 24.71, 24.60, 24.55, 24.44; IR (film) 1490, 
1127 cm-1; MS (ESI) 290.1904 (290.1903 calcd for C21H23N, M + H
+). 
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Relative Stereochemistry: nOe 
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Aniline Nucleophile Optimization 
The key findings during optimization studies are highlighted in red. 
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Ligand and Selectivity 
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